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1 Introduction 
1.1 Cardiovascular disease 
Cardiovascular diseases (CVDs) are the number one cause of death worldwide, with an 
estimated 17.1 million deaths in 2004. 82% of CVD deaths are in low- and middle-
income countries (WHO, 2009). CVDs are the leading cause of death in the Austria 
accounting for 45% of overall deaths. Although the mortality rate has decreased by 25% 
since 1990, the CVD related death rate is still 17% higher than the Western European 
average (WHO, 2004). In the United States CVDs accounted for 35.3% of total deaths 
in 2005, with an estimated total cost of $475.3 billion in 2009. Within CVDs coronary 
heart disease accounts for 52% of overall deaths (American Heart Association, 2009). 
A decrease in the number of reported coronary heart diseases (CHDs) as well as the 
higher survival rate following myocardial infarction (MI) led to a recent decline in 
overall death rate due to CHDs. Reduction in CVD is largely a result of improved 
classical risk factor management, such as smoking secession and reduced cholesterol 
diet. The increased survival rate after acute MI is due to the progress in treatment 
methods, such as the use of thrombolytic agents (McGovern et al., 1996).  
Pharmacological and non-pharmacological therapies have been developed which have 
significantly enhanced therapy options for a variety of CVDs. However, the loss of 
cardiomyocytes is irreversible and leads to the development of progressive heart failure. 
Cardiac transplantation is limited due to a shortage of donor organs, 
immunosuppression complications, and the possibility of functional failure of the 
transplanted heart (Hassink et al., 2003). 
New therapeutic options for MI patients were made conceivable by the discovery of 
stem cell populations from somatic tissues as well as embryonic stem cells. The better 
understanding of the wide differentiation potential of stem cells led to extensive 
research on tissue renewal. So far, embryonic stem cells, bone marrow mononuclear 
cells, haematopoietic stem cells, mesenchymal stem cells, endothelial progenitor cells, 
skeletal myoblasts, and cardiac stem cells are being investigated for treatments after MI 
(Joggerst and Hatzopoulos, 2009). 
Although progress has been made, only modest results have been achieved by 
increasing tissue renewal of diseased hearts using stem cell therapy (Joggerst and 
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Hatzopoulos, 2009). For example, skeletal muscle has been investigated as a 
replacement for cardiac muscle after MI. Skeletal myoblasts have been shown to form 
grafts of mature muscle after injection into diseased or healthy hearts. These grafts can 
contract as a reaction to exogenous stimulation. Although the essential formation of 
electromechanical junctions between cardiac muscle cells and skeletal muscle cells for 
functional integration into heart tissue was shown in vitro, formation could not be 
forced in vivo (Reinecke et al., 2000).  
During the last three decades the heart was thought to be one of the least regenerative 
and post-mitotic organs in the human body. Cardiomyocyte response to stress was 
believed to be limited to hypertrophy and/or cell death (Anversa et al., 2006; Laflamme 
and Murry, 2005). Lately, it has been proposed that myocardial regeneration after 
infarction in the human heart is mediated by multipotent cardiac stem cell-like cells 
(CSCs). These cells are self-renewing but can divide and differentiate into myocytes, 
smooth muscle cells, and endothelial cells (Beltrami et al., 2003; Urbanek et al., 2005). 
In 3 months old mouse hearts the presence of senescent and nonsenescent myocytes was 
observed, indicating that these cells do not have a common origin. These cells are more 
likely products of a time dependent activation and differentiation of progenitor cells of 
the heart (Rota et al., 2007). Undifferentiated Y-chromosome-positive cells were found 
in female hearts after transplantation into male patients. These cells had translocated to 
the grafted heart and could give rise to coronary arteries, capillaries, and myocytes 
(Quaini et al., 2002). The heart is now viewed as a self-renewing organ in which 
myocyte regeneration occurs throughout the lifespan of the organism (Anversa et al., 
2006). 
CSCs raise hope for new treatment possibilities for MI patients. If in vivo activation of 
CSCs could be triggered after myocardial infarction, healing processes of affected tissue 
could be induced (Joggerst and Hatzopoulos, 2009).  
1.2 Stem cells 
Stem cells can be defined as cells that have the choice between self-renewal and 
differentiation upon every division, without depleting the stem cell pool. This choice is 
influenced by signals from the microenvironment or stem cell niche (Alenzi et al., 2009; 
Ying et al., 2003). Stem cells help to maintain tissue homeostasis by replacing 
terminally differentiated, aged, and injured cells (Boiani and Scholer, 2005). Stem cells 
are characterized by self-renewal and potency. Self-renewal means that stem cells can 
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proliferate indefinitely giving rise to identical daughter cells without the loss of 
stemness character, potency or going into senescence (Silva and Smith, 2008). Potency 
describes the ability of stem cells to give rise to at least one, or various somatic cell 
types (Donovan and Gearhart, 2001). Potency can be classified into totipotency, 
pluripotency, multipotency, and unipotency. 
Totipotency means the ability of a single cell to give rise to all cell types required 
during embryogenesis, including extra-embryonic tissue, in order to produce a viable 
animal. The fertilized egg is a totipotent cell (Western, 2009). Recently, it has been 
shown that normal, fertile animals can be developed from both inner and outer 
blastomers of the 16-cell embryo, but not the 32-cell embryo (Suwinska et al., 2008). 
Pluripotency defines the ability of a single cell to give rise to all cells of an embryo but 
not extraembryonic trophectoderm (Boiani and Scholer, 2005; Donovan and Gearhart, 
2001). 
Multipotency describes the ability of one stem cell to give rise to a number of 
differentiated cells. Potency is limited compared to pluripotent stem cells. These stem 
cells are tissue specific and are not isolated from the inner cell mass. Haematopoetic 
stem cells are an example of multipotent stem cells which can differentiate into at least 
eight cell types including erythrocytes and white blood cells (Alenzi et al., 2009). 
Unipotency means that one stem cell can give rise to only one specialized cell type. 
Spermatogonial stem cells in the testis are an example of unipotent stem cells. These 
cells can only differentiate into spermatozoon or remain in self-renewal (Donovan and 
Gearhart, 2001).  
It has been believed that stem cells from a certain tissue can only differentiate into cells 
native to this tissue. More recently it has been suggested that these cells also have the 
potential to differentiate to other cell types (Jiang et al., 2002). 
Embryogenesis and derivation of stem cells 
After fertilization of the mouse oocyte, cell division and compaction take place during 
mouse embryogenesis (Figure 1). The outer cells of the morula stage form the 
trophectoderm (TE), the inner cells form the pluripotent inner cell mass (ICM) (Boiani 
and Scholer, 2005; Niwa, 2007).  
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The ICM gives rise to the epiblast and primitive endoderm (PrE). PrE is the precursor of 
extraembryonic endoderm essential for the nutrition supply of the embryo. The epiblast 
gives rise to the primitive ectoderm which develops into all three germ layers forming 
the embryo (Boiani and Scholer, 2005; Niwa, 2007).  
The primitive ectoderm is the only cell lineage maintaining pluripotency at the egg 
cylinder stage and gives rise to all three germ layers (Niwa, 2007). Embryonal 
carcinoma cells (ECCs) can be derived from primitive ectoderm (Boiani and Scholer, 
2005). Primitive ectoderm cannot form TE or PrE (Gardner and Rossant, 1979; Niwa, 
2007; Shimosato et al., 2007). The experimental ability to isolate ESCs and ECCs is lost 
after initiation of gastrulating. Primordial germ cell (PGC) are found in gastrula stage 
(Boiani and Scholer, 2005). 
 
Figure 1 Mouse embryogenesis. The inner cell mass (ICM) gives rise to the epiblast and the primitive endoderm. 
The epiblast forms the embryo proper while the primitive endoderm gives rise to the extraembryonic endoderm 
forming extraembryonic tissue. Only the primitive endoderm contains pluripotent stem cells at the egg cylinder stage. 
ESCs can be derived from blastocysts, ECCs from late blastocysts, and PGCs from gastrula stage (Boiani and 
Scholer, 2005). 
1.3 Pluripotent stem cells 
There are three types of pluripotent stem cells: embryonal carcinoma cells (ECCs), 
embryonic germ cells (EGCs), and embryonic stem cells (ESCs) (Donovan and 
Gearhart, 2001) (Figure 2). Beyond that, pluripotent stem cells may be generated by 
reprogramming somatic cells; this is referred to as induced pluripotency. 
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Figure 2 Pluripotent stem cell origins in humans. Pluripotent cells can be derived from the inner cell mass of a 
blastocyst (embryonic stem cells), from primordial germ cells (embryonic germ cells), and from testicular tumors in 
adults (embryonal carcinoma cells). (Donovan and Gearhart, 2001) 
Embryonal carcinoma cells  
Spontaneous testicular germ cell tumors can form during primordial germ cell 
development. Embryonal carcinoma cells are derived from such germ cell tumors 
(Stevens, 1967). 
Embryonic germ cells  
Murine embryonic germ cells originate from in vitro culture of mouse primordial germ 
cells (PGCs) on feeder layers (Matsui et al., 1992). 
Embryonic stem cells 
Murine ESCs are derived from the inner cell mass of late mouse blastocysts (Martin, 
1981).  
Induced pluripotent stem cells 
Induced pluripotent stem cells (iPS cells) are generated by reprogramming somatic 
cells.  
• iPS cells can be created by a fusion of ESCs with somatic cells, giving rise to 
tetraploid cells displaying ESC properties in morphology, growth rate, and 
antigen expression. Differentiation of these cells can give rise to cells of all three 
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germ layers. iPS derived from fusion of ESCs and somatic cells still contain the 
chromosomes of ESC which is a major disadvantage for possible therapeutic use 
(Cowan et al., 2005).  
• Furthermore, iPS cells can be generated from mouse embryonic fibroblasts by 
introduction of Oct3/4, Sox2, Klf4, and c-Myc. Generated iPS can trigger tumor 
formation after subcutaneous transplantation in nude mice. Although these cells 
show morphology and growth properties of ES cells, their gene expression 
profile is compromised (Takahashi and Yamanaka, 2006).  
1.4 Murine embryonic stem cells 
ESCs have, along with pluripotency and self-renewal, also the ability to form primary 
chimaera (Silva and Smith, 2008). Upon transplantation of mESCs into the ICM of E3.5 
blastocysts they can completely integrate into the developing embryo giving rise to high 
rates of chimaerism (Boiani and Scholer, 2005).  
For a long time pluripotency was defined as the ability of one cell to differentiate into 
cells of all three germ layers, without contributing to the trophectoderm lineage 
(Beddington and Robertson, 1989; Boiani and Scholer, 2005; Donovan and Gearhart, 
2001). Recently it was proposed that ICM cells as well as mESCs still possess the 
ability to form trophectoderm under certain conditions (Niwa et al., 2005; Pierce et al., 
1988). Therefore ESCs lack the self-organizing ability to create a whole organism while 
maintaining the capacity to form all necessary cell types including trophectoderm (Niwa 
et al., 2005). Upon subcutaneous injection into athymic mice mESC form 
teratocarcinomas containing derivates of all three germ layers within 6 weeks (Martin, 
1981).  
In vitro mESCs can be maintained pluripotent by co-culture of mESC with mitotically 
inactivated fibroblast feeder cells or in the presence of Leukemia Inhibitory Factor 
(Martin, 1981; Thompson et al., 1989).  
1.5 Embryoid Body formation in mice 
When mESCs are cultured in suspension they form round homogenous cell aggregates 
termed Embryoid Bodies (EBs). EBs consist of an inner core of mESCs coated by a 
single layer of endoderm-like cells. Their name derives from their similarity to the ICM 
of mouse embryos (Martin, 1981). 
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EBs were first made with embryonal carcinoma cells (Martin and Evans, 1975). Cells 
were cultured in the absence of feeder layers and aggregates of ECCs had formed after 5 
days displaying an outer layer of endodermal cells. The presence of feeder layers or 
gelatin coating of culture plates prevented formation of EBs (Martin and Evans, 1975). 
Differentiation was observed upon the attachment of EBs on new culture plates. Cells 
started migrating and formed a halo around cores. Cell lysis and necrosis was observed 
in core regions of EBs. EBs made from ECCs formed keratinizing epithelium, 
endodermal cysts, fibroblasts, cartilage, adipose tissue, beating muscles, pigmented 
cells, and neural cells (Martin and Evans, 1975). Similar organized structures were 
formed in both EB systems but frequency of these structures was much higher in 
mESC-derived EBs. EBs derived from mESCs formed more mesoderm-derived 
structures compared to EBs derived from ECCs (Doetschman et al., 1985) 
EBs derived from mESCs form endoderm, mesoderm, ectoderm, and basal lamina 
between days 3 to 8 of development. By day 5, EB development reaches a state similar 
to the egg-cylinder stage of a 5-day old embryo. Between day 8 and 10 formation of 
cystic structures secreting alpha-Fetoprotein and Transferrin takes place, a characteristic 
of visceral yolk sac endoderm in embryos (Dziadek and Adamson, 1978). These 
structures are analogous to the visceral yolk sac of the postimplantation embryo 
(Doetschman et al., 1985). By day 8 of differentiation one third of EBs develop 
rhythmically contracting areas which continue to beat for over a week (Doetschman et 
al., 1985). In conclusion, EB formation mimics early embryogenesis to a certain degree.  
1.6 Maintaining stem cell pluripotency 
In order to potentially use ESCs for therapy it is crucial to understand the complex 
intrinsic regulatory mechanisms of these cells. Although progress has been made in 
understanding the function of the three identified stemness factors Oct3/4, Sox2, and 
Nanog, the extensive mechanisms controlling ESC fate have yet to be determined 
(Macarthur et al., 2009). 
1.6.1 Transcription factor Sox2 
Sox2 is a member of the Sox (SRY-related HMG box) gene family and contains one 
HMG (High Mobility Group)-DNA binding domain (Kamachi et al., 2000). Sox2, like 
Oct3/4, was shown to be expressed in the ICM, the epiblast, and in germ cells (Avilion 
et al., 2003; Pesce and Scholer, 2000). Furthermore Sox2 is expressed by multipotent 
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progenitors in the extraembryonic ectoderm and is a marker for precursor cells within 
the central nervous system (Avilion et al., 2003). 
1.6.2 Transcription factor Oct3/4 
Oct3/4 (octamer binding protein) belongs to the POU (Pit-Oct-Unc) transcription factor 
family and is encoded by the Pou5f1 locus. Presence of Oct3/4 is essential to maintain 
stem cells in an undifferentiated state. Oct3/4 knockout embryos die at time of 
implantation due to loss of pluripotency (Avilion et al., 2003; Nichols et al., 1998; Niwa 
et al., 2000). Repression of Oct3/4 in mESCs leads to differentiation to trophectoderm 
and consequential loss of pluripotency (Figure 3). Over expression of Oct3/4 in mESCs 
leads to differentiation of stem cells to primitive endoderm and mesoderm. Therefore 
the balance of Oct3/4 expression seems crucial in determining the cell fate of mESCs 
(Niwa et al., 2000). 
 
Figure 3 Influence of Oct3/4 and Nanog on embryogenesis. Absence of Oct3/4 expression in morula cells leads to 
differentiation to trophectoderm. Expression of Nanog determines cell fate between epiblast and primitive endoderm 
(adapted from Boiani and Scholer, 2005). 
1.6.3 Transcription factor Nanog 
Nanog is a homeobox protein and plays a fundamental role in the maintenance of 
pluripotency of the ICM and ESCs (Mitsui et al., 2003). The Nanog expression rate 
determines cell fate in epiblast cells. Nanog expressing cells remain pluripotent and 
cells lacking Nanog differentiate into primitive endoderm (Figure 3) and give rise to 
extraembryonic tissue (Mitsui et al., 2003). Expression of elevated levels of Nanog can 
prevent differentiation of mESCs in the absence of LIF, while physiological levels of 
Nanog cannot (Boiani and Scholer, 2005; Mitsui et al., 2003). The Nanog promoter 
region contains two binding sites for the tumor suppressor p53 and therefore Nanog 
expression can be directly suppressed by p53 (Lin et al., 2005). 
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1.6.4 Interaction of stemness factors 
Oct3/4 and Sox2 can form a complex and regulate gene transcription. The Oct3/4-Sox2 
complex can bind to the FGF4 (fibroblast growth factor 4) enhancer region and thereby 
promote transcriptional activation of FGF4. FGF4 is expressed in the ICM and epiblast 
and is essential during embryogenesis (Niswander and Martin, 1992; Rappolee et al., 
1994; Yuan et al., 1995). Furthermore the Oct3/4-Sox2 complex can upregulate 
transcription of Nanog and Oct3/4 (Kuroda et al., 2005; Okumura-Nakanishi et al., 
2005; Rodda et al., 2005). Sox2 expression is regulated by POU factor binding sites in 
the upstream Sox2 enhancer and can therefore be controlled by Oct3/4 (Catena et al., 
2004). Oct3/4, Sox2, and Nanog have a positive feedback on their gene expression 
thereby contributing to self-renewal of mESCs (Boyer et al., 2005) (Figure 4).  
In conclusion, stemness factors are regulated by an interwoven network with many 
feedback loops. Although first insights have been gathered, much more has to be 
discovered to fully understand the regulation of pluripotency.  
 
Figure 4 The stemness factor regulatory loop. Nanog influences expression of Oct3/4 and Sox2. Complex of 
Oct3/4 and Sox2 can regulate Nanog transcription. Auto-regulatory feedback loops are proposed for all stemness 
genes. (Macarthur et al., 2009). LIF might positively influence stemness factor Sox2 and Nanog transcription via the 
Stat3, and Akt pathway and inhibit transcription of Nanog via the MAPK pathway. Upregulation of Sox2 and Nanog 
leads to an activation of Oct3/4 transcription (adapted from Niwa et al., 2009). 
1.7 Leukemia Inhibitory Factor 
Leukemia Inhibitory Factor (LIF) belongs to the interleukin (IL)-6 cytokine family. The 
mouse genome encodes for three isoforms of LIF, namely M-LIF (extracellular matrix 
associated), D-LIF (diffusible), and T-LIF (N-terminal truncated) (Gearing et al., 1987; 
Haines et al., 1999; Rathjen et al., 1990b). M-LIF and D-LIF are extracellular proteins 
that are differently expressed during embryogenesis by various embryonic cell types 
(Rathjen et al., 1990a). T-LIF is retained within the cell (Haines et al., 1999). A soluble 
form of the mLIF receptor termed LIF-binding protein (LBP) is present at high levels in 
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serum and even more increased in pregnant mice. LBP most likely prevents systemic 
effects of locally produced LIF (Layton et al., 1992). 
LIF induces heterodimerization of glycoprotein 130 (gp130) receptor and LIF receptor 
(LIFR) leading to phosphorylation and activation of receptor-associated-Janus Kinases 
(JAKs). This leads to recruitment and phosphorylation of Stat3 (signal transducer and 
activator of transcription 3), followed by translocation of pStat3 to the nucleus. 
Alternatively to the activation of the Stat3 pathway, LIF can activate the mitogen-
activated protein kinase (MAPK) pathway (Figure 5) (Davey and Zandstra, 2006; 
Hirano et al., 1997).  
LIF can maintain mESCs in self-renewal and suppress differentiation via the Stat3 
pathway (Niwa et al., 1998; Raz et al., 1999; Williams et al., 1988). Furthermore LIF 
can enhance survival and proliferation in primordial germ cells (De Felici and Dolci, 
1991; Matsui et al., 1991). In the absence of LIF mESCs gradually lose responsiveness 
for LIF prior to loss of stemness factor expression (Oct3/4 and Nanog) and undergo 
consequential differentiation. Expression of Stat3, gp130, and LIFR are essential for 
LIF responsiveness and the expression rate correlates with the level of Stat3 activation 
(Davey et al., 2007). Cells do not differentiate immediately upon LIF deprivation. It is 
suggested that an autocrine cell density-dependent LIF production can transiently aid 
maintenance of pluripotency in mESCs in the absence of exocrine LIF (Zandstra et al., 
2000). Autocrine expression of (non-LIF) gp130 ligands was also observed in the 
absence of LIF (Davey and Zandstra, 2006). The endogenous signals supporting Stat3 
activation in the absence of LIF cannot fully maintain Stat3, gp130, and LIFR 
expression. Consequently Stat3 activation decreases over time eventually leading to 
differentiation, if LIF deprivation persists (Davey et al., 2007).  
The cardiac marker Nkx2.5 contains Stat3 DNA binding sites in its promoter region. 
Therefore a direct influence of Stat3 expression on Nkx2.5 expression and 
cardiomyogenesis is possible (Foshay et al., 2005). 
LIF plays a role in many different cell types and various stages of development. For 
example LIF has hematopoietic effects such as the enhancement of megakaryocyte and 
platelet production (Metcalf et al., 1990; Metcalf et al., 1992). LIF can indirectly 
regulate bone resorption (Martin et al., 1992), act as a survival factor in fetal sensory 
neurons (Hendry et al., 1992; Thaler et al., 1994), and promote growth and survival of 
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oligodendrocytes in vitro (Mayer et al., 1994). Uterine expression of LIF is essential for 
implantation and its absence in LIF-/- mice is embryonic lethal (Stewart et al., 1992). 
LIFR expression of embryos is not essential for implantation but the disruption of LIFR 
causes perinatal death (Ware et al., 1995).  
 
Figure 5 LIF signaling. LIF induces heterodimerization of LIFR and gp130. The Stat3 pathway, or alternatively, the 
MAPK pathway is activated. pStat3 translocates into the nucleus and positively influences ESC renewal while the 
MAPK pathway can induce differentiation. 
1.8 Bone Morphogenetic Protein 2 
Bone Morphogenetic Protein 2 (BMP2) belongs to the transforming growth factors-β 
(TGF- β) superfamily (Wozney et al., 1988). Mammalian BMP2 shows 75% amino acid 
identity to Drosophila protein DPP (decapentaplegic) which is responsible for body 
pattern formation steps during Drosophila development (Capovilla et al., 1994; 
Ferguson and Anderson, 1992; Zhang and Bradley, 1996).  
BMPs signal through heterodimerization of type I and type II receptors. Type I 
receptors BMPR-IA (ALK3) and BMPR-IB (ALK6) have been identified in mammals, 
while the expression of BMPR-IB is more restricted. BMPR-II (type II receptor) binds 
BMP-2 weakly in the absence of type I receptors, while type I receptors bind BMP even 
in the absence of type II receptors. This stands in contrast to TGF-β receptor systems. 
Both receptors are serine-threonine kinase receptors and are required for subsequent 
signal transduction. After type I receptor is activated by type II receptor it mediates 
signaling through the activation of Smad 1/5/8 by phosphorylation (Figure 6). BAMBI 
(BMP and Activin Membrane Bound Inhibitor homolog) is a pseudoreceptor for serine-
threonine receptors and structurally related to type I receptors. It can stably interact with 
type I and II receptors and inhibit BMP/TGF induced signaling in a ligand independent 
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fashion. (Kawabata et al., 1998; Liu et al., 1995; Miyazono et al., 2009; Onichtchouk et 
al., 1999; Rosenzweig et al., 1995; Sekiya et al., 2004; ten Dijke et al., 1994).  
 
Figure 6 BMP signaling. BMP2 binds BMPR-I and BMPR-II, which leads to phosphorylation and activation of 
receptor I by receptor II. BMPR-I can now phosphorylate and activate Smad1/5/8. pSmad1/5/8 can associate with 
Smad 4 and translocate to the nucleus, this can be prevented by Smad6/7. Gene transcription is influenced by 
interaction with transcriptional co-activators or co-repressors. Extracellular BMP antagonist Noggin can bind BMP 
ligand and block signaling. Pseudo-receptor BAMBI can inhibit BMP signaling by forming a stable complex with 
BMP receptors. 
BMP2 is essential during early mouse embryonic development. In BMP2 deficient 
embryos amnion/chorion formation fails and cardiac development is abnormal, thereby 
showing a role for BMP2 in embryonic and extraembryonic development (Zhang and 
Bradley, 1996). High expression levels of BMP2 are detected in the myocardial layer of 
the mouse heart at day E9.5 (Zhang and Bradley, 1996). Treatment of mESCs with 
BMP2 for 24 h prior to EB formation results in a more than twofold increase of 
contracting areas and enhances myofibrillogenesis compared to untreated mESCs 
(Behfar et al., 2002). However, no effect on cardiomyocyte induction by stimulation of 
mESCs with BMP2/BMP4 was reported by Yuasa et al. 2005. 
The BMP antagonist Noggin is expressed on day E7.5 in the cardiac crescent and on 
day E8.0 in the late crescent, but is barely expressed in the linear heart tube on day E8.5 
(Yuasa et al., 2005). Treatment of mESCs with Noggin before or after EB formation 
does not increase the formation of beating EBs. Only treatment of mESCs with Noggin 
3 days prior to EB formation followed by treatment on day 0 results in an increase of 
beating EBs (Yuasa et al., 2005). These data indicate that BMP signaling is strongly 
time frame dependent during heart formation. Induction of an acute myocardial 
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infarction in mice and subsequent injection of mES cells result in a reduction of fibrosis 
in the affected area. When these mESCs are previously treated with a combination of 
LIF and BMP2, typical cardiomyocyte morphology and striation patterns are observed 
28 days post injection. Untreated cells show more differentiation towards endothelial 
cells 28 days post injection (Rajasingh et al., 2007). 
In chick BMP2 is able to induce expression of myocardial lineage marker Nkx2.5 and 
GATA4 in ectopic locations. Addition of BMP antagonist Noggin prevents 
differentiation of precardiac mesoderm into heart tissue (Schultheiss et al., 1997; 
Zimmerman et al., 1996). BMP2 is insufficient to support viability of precardiac and 
non-precardiac mesoderm (Lough et al., 1996). Implantation of BMP2 loaded beads in 
chick can expand Nkx2.5 expression in the anterior paraxial mesoderm specifically. In 
vitro culture of anterior paraxial mesoderm combined with BMP2 results in formation 
of robust cardiomyocytes (Schultheiss et al., 1997). 
Expression of BMP2/4 overlaps with the expression of inhibitor of differentiation (Id) 
proteins during embryogenesis. Smad-binding elements are localized in the Id1 
promoter region and may also exist in the Id3 promoter region. Expression of Id1 and 
Id3 is nearly identical during development and might therefore be directly regulated by 
BMP-induced Smads (Korchynskyi and ten Dijke, 2002; Yanagisawa et al., 2001). Id1 
and Id3 double-knockouts are embryonic lethal at E13.5 (Lyden et al., 1999). After loss 
of Id1 mouse embryonic fibroblasts go into premature senescence (Ruzinova and 
Benezra, 2003). In tissue culture overexpression of Id1 in endothelial cells can delay 
senescence but not completely block it (Kiyono et al., 1998; Tang et al., 2002). 
Upregulation of Id expression is not sufficient for immortalization although elevated 
levels might be necessary to maintain a highly proliferative state in tumor cells or tissue 
culture (Ruzinova and Benezra, 2003).  
In conclusion BMP2 can both induce and inhibit differentiation via the Smad 1/5/8 
signaling pathway. During heart development BMP2 signaling appears to be strongly 
timeframe-dependent. 
1.9 Secreted Protein Acidic and Rich in Cystein  
Secreted Protein Acidic and Rich in Cystein (SPARC), also termed Osteonectin or BM-
40, is a 32 kDa Ca2+ binding glycoprotein belonging to the matricellular family of 
proteins. The secreted form of SPARC migrates at 43kDa due to the addition of 
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carbohydrate (Sage et al., 1984). SPARC is produced by many cell types and can 
modulate growth factor activity, inhibit the cell-cycle, and can function as a 
counteradhesive protein (Brekken and Sage, 2000).  
SPARC is a highly conserved protein. Human and mouse SPARC are 92% identical 
(Brekken and Sage, 2000). The murine SPARC is encoded by 10 exons localized on 
chromosome 11 over a 26.5kb span. Exon 1 is untranslated. SPARC consists of an 
extracellular Ca2+ binding module, a Follistatin-like module, and an acidic module 
(Figure 7). 
 
Figure 7 Structure of human SPARC. Module 1 is highly acidic and function is unknown. Module 2 contains 
structures homologue to repeated domains in follistatin. It might have a function in recruitment to cell surface 
receptors. Module 3 executes the Ca2+ binding activity (Brekken and Sage, 2000). 
Expression of SPARC is partially and temporally regulated during development. In the 
adult it is mainly found in tissues undergoing repair or remodeling (Brekken and Sage, 
2000; Yan and Sage, 1999). During mouse embryogenesis SPARC expression is 
detected on day E9 in the heart primordia (Brekken and Sage, 2000).  
SPARC can be found in cell culture media, structures outlining the Golgi apparatus, in 
nuclei of dividing cells, and in the cytoplasm during metaphase and anaphase (Brekken 
and Sage, 2000; Gooden et al., 1999).  
SPARC protein levels were found to be strongly increased in the left ventricle of the 
murine heart 7 days after MI (Schellings et al., 2009). SPARC null mice have a much 
higher risk of dying from cardiac rupture after myocardial infarction (41%) compared to 
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wildtype mice (9%). While overexpression of SPARC does not affect infarct size, it 
does prevent cardiac dysfunction and dilatation. Increased SPARC levels have a 
positive effect on the healing process after MI. In SPARC null mice the cardiac rupture 
after MI can be prevented by treatment with TGF-β, indicating SPARC mediated TGF-β 
signaling (Schellings et al., 2009). 
Extracellular SPARC binds to integrins-β1 in lens epithelial cells. Integrin-β1 can 
interact with integrin-linked kinase (ILK) via its cytoplasmic tail and thereby modify its 
activity (Weaver et al., 2008). In adipocyte differentiation SPARC induces β-catenin 
signaling through ILK. In the presence of siRNA against ILK this effect is no longer 
observed. Therefore SPARC can modulate Wnt pathway and β-catenin through ILK 
signaling (Nie and Sage, 2009). In myoblasts, SPARC inhibits phosphorylation of the 
FGFR1 induced by FGFR1 ligand FGF-2, without affecting interaction between 
receptor and ligand. The inhibition of FGF signaling induces differentiation to 
myocytes. SPARC inhibits ERK activation by FGFR1 and thereby influencing the 
MAPK pathway. SPARC does not affect Akt (thymoma viral proto-oncogene 1) 
activation (Motamed et al., 2003). In murine mesangial cells SPARC induces 
expression of TGFβ-1 on both mRNA and protein level (Francki et al., 1999). 
In the EB system SPARC induces the expression of cardiac markers Nkx2.5 and α-
MHC (α-Myosin Heavy Chain) in cardiomyocytes. Furthermore, within 4 h BMP2 
expression can be induced by SPARC, both in CBs and in fetal cardiomyocytes. Only 
BMP2 in combination with SPARC could induce Nkx2.5 expression and promote 
cardiomyogenesis (Stary et al., 2005). 
1.10 Desmin 
Desmin is a subunit of the muscle-specific type III intermediate filaments and is 
expressed in the murine precardiac mesoderm starting day E7.5 (Kuisk et al., 1996). 
Desmin was shown to directly bind to DNA via its amino-terminus (Li et al., 2003; 
Tolstonog et al., 2005). Deletions in the amino-terminal of Desmin (amino-acids 1-48) 
delayed and hampered cardiomyogenesis and inhibited smooth muscle formation in the 
EB system. DesminΔ1-48 inhibited expression of Nkx2.5 and MEF2c in differentiating 
cardiomyocytes on day 6 and seemed to interfere with onset of cardiomyogenesis. 
Constitutive overexpression of Desmin promoted differentiation of mESCs and 
transiently upregulated Nkx2.5. Although Desmin seems to play a supporting role 
during cardiomyogenesis, it is not sufficient to drive mESCs into the cardiomyocyte 
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lineage (Hofner et al., 2007; Hollrigl et al., 2002). Gene targeting of Desmin leads to 
extensive myocyte cell death and to heart failure in mice (Milner et al., 1999; Milner et 
al., 1996). 
2 Rationale 
Cardiovascular Diseases account for almost 1 out of 2 deaths in Austria. Loss of 
cardiomyocytes after acute myocardial infarction is currently irreversible. Recently, 
cardiac progenitor cells have been isolated by various groups. Reactivation of dormant 
cardiovascular progenitor cells in the heart would increase tissue renewal after acute MI 
and could thereby prevent progressive heart failure.  
The mechanisms underlying self-renewal of ESCs are only partly understood and even 
less is known about somatic progenitor cells. Therefore it is important to determine the 
differences and similarities of mESCs and progenitor cells of the heart. mESCs are 
isolated from the inner cell mass and are in some sense an in vitro tissue culture artifact. 
So far it is unclear if the self-renewal of cardiac progenitor cells can be triggered by the 
same factors as in mESCs or whether they require a specialized microenvironment 
entirely different from mESCs. The better understanding of the maintenance of 
multipotency of cardiac progenitor cells will aid in vitro culture. Indefinite culture of 
cardiac progenitor cells will significantly promote research potential compared to 
repeatedly isolating new cardiac progenitor cells. The establishment of an in vitro 
system to mimic cardiomyogenesis will further benefit research. 
Investigation of the limitations and the potential of cardiovascular progenitor cells will 
contribute to the understanding of the regenerative potential of the heart. Furthermore, 
cardiovascular progenitor cells provide a system to study the signaling mechanisms 
initiating cardiomyocyte differentiation in the adult heart opposed to heart development 
during embryogenesis.  
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3 Abbreviations 
  
AcNPV Autographa california nuclear polyhedrosis virus 
Akt thymoma viral prot-oncogene 1 
Alk3 bone morphogenetic protein receptor, type IA  
Alk4 activin A receptor, type 1B  
BAMBI BMP and activin membrane bound inhibitor homolog 
BMP bone morphogenetic protein 
CB cardiac body 
cDNA complementary deoxyribonucleic acid 
CHD coronary heart disease 
CMV cytomegalovirus  
CSC cardiac stem cell-like cell 
cTNT cardiac troponin T 
CVD cardiovascular disease 
CVPC cardiovascular progenitor cell 
D-LIF diffusible leukemia inhibitory factor 
DMEM dulbecco's modified eagle medium 
DMSO dimethylsulfoxid 
dNTP deoxy nucleotide triphosphate 
DTT dithiothreitol 
EB embryoid body 
ECC embryonal carcinoma cell 
EDTA ethylenediaminetetraacetic acid 
ERK mitogen-activated protein kinase 1 
ESC embryonic stem cell 
FGF4 fibroblast growth factor 4 
FGFR1 fibroblast growth factor receptor 1 
GATA4 GATA-binding protein 4 
GFP green fluorescence protein 
gp130 glycoprotein 130 
GSKα/β glycogen synthase kinase alpha/beta 
HDAC histone deacetylase 
HMG high mobility group 
HRP horseradish peroxidase 
ICM inner cell mass 
IL6 interleukin 6 
ILK integrin linked kinase 
iPS cell induced pluripotent stem cell 
JAK janus associated kinase 
LBP leukemia inhibitory factor binding protein 
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MAPK mitogen activated protein kinase 
MEF2C myocyte enhancer factor 2c 
Mesp1 mesoderm posterior 1 
MI myocardial infarction 
M-LIF matrix-associated leukemia inhibitory factor 
Nkx2.5 NK2 transcription factor related, locus 5 
Oct3/4 octamer-binding transcription factor 3/4 
OSMR oncostatin M receptor 
PCR polymerase chain reaction 
PGC primordial germ cell 
Pou5f1 POU domain, class 5, transcription factor 1 
PrE primitive endoderm 
RT-PCR reverse transcription polymerase chain reaction 
SDS sodium dodecyl sulfate 
SF Spodoptera frugiperda 
siRNA short interfering ribonucleic acid 
SMA smooth muscle actin 
Smad mothers against decapentaplegic homolog 
Sox2 SRY-related box 2 
SPARC secreted protein acidic and rich in cystein 
Stat3 signal transducer and activator of transcription 3 
T brachyury 
TE trophectoderm 
TGF-β transforming growth factor-β 
T-LIF truncated leukemia inhibitory factor 
Wnt wingless-related MMTV integration site  
α-MHC α-myosin heavy chain 
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4 Results 
4.1.1 HDAC1 expression and its correlation with HDAC2 and Nkx2.5 expression 
Cardiovascular Progenitor Cells (CVPCs) are derived from neonatal hearts of N1-2 
neoR mice. These mice carry a disruption of one allele of the histone deacetylase 1 
(HDAC1) locus by a neomycin resistance cassette. An over expression of HDAC1 was 
shown to negatively affect Nkx2.5 expression and cardiomyogenesis, whereas an RNAi 
knockdown of HDAC1 promoted both Nkx2.5 expression and cardiomyogenesis (Liu et 
al., 2009).  
We therefore wanted to investigate if HDAC1 expression was downregulated in 
HDAC1 heterozygous CVPC clone A5. We compared HDAC1 mRNA expression level 
of CVPCs to murine embryonic stem cells (mESCs) homozygous and heterozygous for 
HDAC1. If HDAC1 expression proved to be downregulated in CVPCs, we wanted to 
see if HDAC2 is upregulated in response. 
mESCs 663 are homozygous for the HDAC1 wildtype allele. mESC line 662 are 
derived N1-2 neoR mice and carry a heterozygous disruption of the HDAC1 allele. As 
seen in Figure 8A HDAC1 expression on mRNA level is more abundant in mESC 663 
(HDAC1 +/+) and reduced in mESCs 662 (HDAC1 +/-). HDAC2 is upregulated in 
mESC 662 (HDAC1 +/-) compared to wildtype. No reduction of HDAC1 expression 
was found in HDAC1 heterozygous CVPC clone A5 compared to mESCs 663  
(HDAC1 +/+) (Figure 8B). 
 
Figure 8 mRNA expression of HDAC1 and HDAC2. GAPDH was used to balance cDNA in RT-PCR analysis. 
Expression of HDAC1 and HDAC2 mRNA level of mESCs 663 (HDAC1 +/+) and 662 (HDAC1 +/-) is shown in 
(A). Expression of HDAC1 mRNA level in CVPCs and mESC 663 is shown in (B). HDAC1 is down regulated in 
HDAC1 heterozygous mESCs, while HDAC2 is upregulated.  
Next we wanted to see how HDAC2 is expressed in CVPC clone A5 compared to 
mESC 662 (HDAC1 +/-) and 663 (HDAC1 +/+). Figure 9 shows that HDAC2 is not 
upregulated in CVPC clone A5 compared to wildtype mESCs 663. HDAC2 was 
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upregulated in mESCs 662 heterozygous for HDAC1. Level of HDAC2 expression in 
CVPCs was reduced compared to mESCs 662 (HDAC1 +/-). 
 
Figure 9 HDAC2 Expression of mESCs and CVPCs. mESCs 663 (HDAC1 +/+), 662 (HDAC1 +/-), and CVPC 
clone A5 (HDAC1 +/-) were screened for HDAC2 expression on mRNA level. cDNA amount used was balanced by 
GAPDH expression. cDNA was diluted 1:1; 1:1.33; 1:2; and 1:4. HDAC2 expression is upregulated in HDAC1 +/- 
cells. 
Furthermore, we wanted to investigate a possible connection between levels of HDAC1 
and Nkx2.5 in our CVPC cell lines as described by Liu et al. (2009). Unfortunately, 
Nkx2.5 levels were too low to achieve satisfying results. Nkx2.5 levels of wildtype 
mESCs 663 were not significantly lower than the Nkx2.5 mRNA level of the 
heterozygous cell line mESC 662 (data not shown). Expression of Nkx2.5 on mRNA 
level was lower in CVPCs than in HDAC1 heterozygous mESC line 662 (Figure 10). It 
was surprising that mESCs 662 and 663 expressed Nkx2.5 in the undifferentiated state, 
since Nkx2.5 expression was never observed in mESC line AB2.2. 
Expression rate of HDAC1, HDAC2, and Nkx2.5 of CVPC clone A5 was 
approximately the same as the expression rate of these genes in the HDAC +/+ cell line 
mESC 663. 
 
Figure 10 Nkx2.5 expression of mESC and CVPCs. Nkx2.5 mRNA levels were compared in CVPC (HDAC +/-) 
and mESCs 662 (HDAC +/-). Nkx2.5 levels were very low, therefore template amount had to be doubled.  
We could show that HDAC1 heterozygous CVPC clone A5 expressed HDAC1 at levels 
comparable to homozygous mESC line 663. Expression of HDAC2 and Nkx2.5 were 
not upregulated. Since CVPCs behaved like wildtype cells in these aspects, we could 
not show a connection between expression of Nkx2.5 and HDAC1 in CVPCs.  
4.1.2 Karyotyping 
CVPC isolation procedure included a co-culture of CVPCs with mESCs AB2.2. We 
wanted to ensure that our cell lines were not fusion products of somatic cells of the 
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heart and the mESC line AB2.2. If they were fusion products each cell should contain 
80 chromosomes. All CVPC lines were clonally derived, therefore, the vast majority of 
cells was expected to be euploid. In case of fusion cells, the majority should have been 
aneuploid.  
Spindle formation by colchicine treatment was not prevented before karyotyping 
analysis of all eleven CVPC clones. Therefore cells in all cell cycle steps were present 
in our samples. Table 1 shows the total number of counted nuclei and the percentage of 
euploid and aneuploid cells observed. Since in most cases the number of euploid cells 
was higher than 80%, we reasoned that these cells were indeed euploid (Table 1).  
Clone A5 showed 88% euploidy in our original assay. Upon colchicine treatment of 
clone A5, less than 3% aneuplid cells could be detected (over 50 nuclei analyzed). Since 
A5 proved to be 97% and H3 95% euploid we selected these clones for all our 
following experiments. 
CVPC clone % euploid 
 
% aneuploid total counts 
 (≤47 chromosomes) (≥48 chromosomes)  
A3 66.6% 33.3% 18 
A5 88.0% 12.0% 25 
B3 90.0% 10.0% 10 
B5 90.0% 10.0% 20 
C3 60.0% 40.0% 10 
D3 90.9% 9.1% 11 
D5 61.1% 38.8% 18 
E3 82.9% 17.1% 35 
F3 75.0% 25.0% 8 
G3 86.0% 14.0% 43 
H3 95.0% 5.0% 40 
 
Table 1 Chromosome number of CVPC clones. Karotyping was performed without colchicin treatment. Majority 
of aneuploid cells are likely to represent cells undergoing cell division.  
4.1.3 Ground state gene expression on mRNA level 
4.1.3.1 Stemness factors 
In order to verify that CVPCs can indeed have stem cell character we needed to show 
that the three stemness factors – Nanog, Oct3/4, Sox2 - were expressed. mRNA analysis 
showed that all three stemness genes were transcribed in all tested clones on slightly 
varying levels. mRNA expression levels correlated with expression levels seen in 
mESC line AB2.2 (Figure 11). 
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Figure 11 mRNA Expression of stemness factors. mRNA Expression level of stemness factors Sox2, Nanog, and 
Oct3/4 of 9 CVPC clones and mESC line AB2.2 were tested by RT-PCR. GAPDH was used to balance cDNA 
amount. All clones express stemness factors at equal level to ESCs.  
4.1.3.2 Receptor expression 
We wanted to test if CVPCs are potent to react to different external signals. Therefore, 
we tested for the receptor expression of the signaling pathways we were interested in, 
namely the Stat3 and BMP2 pathway.  
OSMR (Oncostatin M receptor) can bind IL6 family member Oncostatin M followed 
by heterodimerization with gp130 and subsequent Stat3 signaling. Interestingly, 
expression of OSMR varied stronger compared to all other tested receptors and proteins. 
OSMR expression was found to be the highest in CVPC clones A3, F3, and G3 (B3 and 
B5 not tested) (Figure 12). The clones A3, E3, and G3 produced the least amount of 
cardiomyocytes in a later experiment (Figure 29). mESC cell line AB2.2 showed weak 
expression of OSMR. High levels of OSMR expression might therefore have a negative 
effect on differentiation in the monolayer system. 
BAMBI (pseudo-receptor BMP and Activin membrane-bound inhibitor homolog) is a 
TGF-β-family type 1 receptor but lacks an intracellular kinase domain. BAMBI inhibits 
TGF-β, BMP, and Activin signaling by preventing formation of receptor complexes in a 
ligand independent manner (Onichtchouk et al., 1999). BAMBI might also play a role in 
determining the onset of cardiomyogenesis. It can enhance the expression of c-Myc and 
cyclinD1 and upregulate Wnt/beta-catenin signaling and therefore result in enhanced 
cell proliferation (Lin et al., 2008). BAMBI was expressed by all tested clones as well 
as by mESC AB2.2, meaning TGF-β, BMP, and Activin signaling can be antagonized in 
CVPCs (Figure 12). 
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ALK4 (Activin receptor-like kinase 4, also referred to as ActRIB) mediates Activin 
signaling via heterodimerization with type II receptors ActRIIA or ActRIIB (ten Dijke 
et al., 1993). ALK4 functions in epiblast and extraembryonic cells to mediate signaling 
required for egg cylinder organization and gastrulation (Gu et al., 1998). All tested 
CVPC clones expressed ALK4 receptor on mRNA level showing that CVPC can also 
respond to Activin signaling (Figure 12). 
Since we were interested in the influence of BMP on cardiomyogenesis we tested for 
expression of receptors responsible for mediating BMP signaling. ALK3 (BMPR-IA) is 
a type I receptor which binds BMP and activates Smad1/5/8 signaling (Kawabata et al., 
1998; ten Dijke et al., 1994). ALK3 was expressed in all cell clones at comparable 
concentrations to AB2.2, meaning CVPCs can respond to BMP2 via the ALK3 receptor 
(Figure 12). 
It is known that LIF plays an essential role in self-renewal of mESCs (Niwa et al., 1998; 
Raz et al., 1999; Williams et al., 1988). In order to see if CVPCs have the potential to 
react to LIF in a likewise fashion as mESCs we tested for the expression of the LIF 
receptor (LIFR). As expected, mESC line AB2.2 expressed LIFR on mRNA level. 
Figure 12 shows that all tested CVPC clones express LIFR on a comparable mRNA 
levels to mESCs AB2.2. Therefore CVPCs have the potential to react to external LIF 
(Figure 12). 
In conclusion, mRNA expression levels of CVPC clones do not vary significantly, with 
the notable exception of OSMR expression levels. CVPCs express the necessary 
receptors to respond to BMP, Activin, and LIF signaling. BAMBI is expressed by 
CVPCs and can antagonize TGF-β, BMP, and Activin signaling. 
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Figure 12 Receptor expression. RT-PCR mRNA expression level of OSMR, BAMBI, ALK4, ALK3 and LIFR in 
mESCs and CVPCs. GAPDH was used to balance cDNA amount. While LIFR is expressed approximately at a 
constant level in all cell types, expression of OSMR receptor varies strongly. 
4.1.4 mRNA expression shift upon differentiation 
We showed mRNA expression levels in the ground state and compared the various 
CVPC clones. Next, we wanted to investigate the change in mRNA expression level 
upon differentiation. We selected clone A5 and H3 for further analysis  
CVPC were left to differentiate in the monolayer culture and in Cardiac Body (CB) 
culture. mRNA isolation took place on day 24 of monolayer culture and on day 17 of 
CB differentiation. EBs were made from mESC AB2.2 and mRNA was isolated on day 
17. Furthermore mRNA of AB2.2, A5, and H3 was isolated on day 0. 
4.1.4.1 Stem cell specific genes 
The expression of stem cell specific genes was tested in CVPC clones A5 and H3 as 
well as in mESC line AB2.2 to monitor differentiation from stem cells to differentiated 
cells. As seen in Figure 13, stemness factor Nanog was expressed in all three cell lines 
in the undifferentiated state (d0) but was depleted upon differentiation (d17, d24). Like 
Nanog, stemness factor Sox2 was highly expressed in the undifferentiated cells. 
Downregulation of Sox2 and Nanog expression in monolayer and CB differentiation 
suggests that CVPCs started differentiating and number of multipotent cells decreased. 
Lowest expression rate of Nanog and Sox2 was observed in differentiated EBs (Figure 
13).  
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Figure 13 Stemness factor expression of differentiated and undifferentiated CVPCs and mESCs. RT-PCR 
mRNA expression levels of stemness factors Nanog and Sox2 is shown. GPADH was used to balance cDNA amount. 
Expression decreases upon initiation of differentiation.  
4.1.4.2 Myocardial genes 
Cardiac stem cell-like cells (CSCs) were also isolated by Oh et al. (2003) and Oyama et 
al. (2007). Oh et al. (2003) reported an expression of MEF2c and GATA4 but not 
Nkx2.5 or α-MHC in the undifferentiated state. Oyama et al. (2007) reported no 
expression of these markers in the undifferentiated state of their isolated CSCs. Here we 
wanted to test if CVPCs express cardiac markers in the self-renewing, undifferentiated 
state. Expression of these markers would indicate a restriction of CVPCs to the cardiac 
lineage. 
The myosin heavy chain (MHC) is the major contractile protein in the heart. Out of all 
isoforms only α-MHC and β-MHC are expressed in cardiac muscle cells. Cardiac α-
MHC is a target for GATA4 (Molkentin et al., 1994). We found an upregulation of α-
MHC in CVPCs which is an indicator of cardiac muscle cell formation (Figure 14). 
Nkx2.5 is an early marker of cardiac differentiation and one of the first transcription 
factors expressed in myocardial progenitor cells. Mice carrying a Nkx2.5 mutation in 
the sequence-specific DNA binding homedomain show abnormal heart formation at 
E8.5 and die between E8.5 and 10.5. Heart looping does not take place but 
cardiomyogenic commitment and myofibrogenesis is not inhibited (Lyons et al., 1995; 
Schultheiss et al., 1995). Nkx2.5 is expressed at low levels in the undifferentiated state 
of CVPCs but not in the undifferentiated state of mESCs. Upon differentiation Nkx2.5 
expression was upregulated and decreased again in late stages of cardiac differentiation 
(Figure 14, data not shown). 
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MEF2c (Myocyte Enhancer Factor 2c) belongs to the family of MADS-box containing 
transcription factors. MEF2c is the oldest known myogenic transcription factor and is 
highly conserved. It is the only transcription factor associated with differentiation of all 
muscle types (Black and Olson, 1998). We found that by day 17 of CB differentiation 
MEF2c expression was downregulated as well. Like Nkx2.5, MEF2c was already 
expressed in the undifferentiated state of CVPCs along with the stemness factors 
Nanog, Oct3/4, and Sox2. We interpreted this as a sign of commitment to the cardiac 
lineage (Figure 14). 
Tropomyosin regulates the interaction of Actin and Myosin. Tropomyosin α/β (α/β -
TM) are essential during murine cardiac development. α-TM is expressed at higher 
levels. α-TM null mice are embryonic lethal between E8 to E11.5 (Rethinasamy et al., 
1998). In undifferentiated CVPCs α-TM was expressed at low levels and was 
upregulated upon differentiation (Figure 14). 
GATA4 is expressed in the developing heart. GATA4-/- mESCs have reduced potential 
to undergo cardiac differentiation (Grepin et al., 1995). In contrast, overexpression of 
GATA4 enhances cardiomyogenesis (Grepin et al., 1997). The GATA4 promoter region 
shows Nkx2.5 binding elements and expression of GATA4 can therefore be influenced 
by Nkx2.5. Like the cardiac markers Nkx2.5 and α-TM, GATA4 is upregulated in 
CVPCs upon differentiation and only expressed at low levels in the undifferentiated 
state (Figure 14). 
We could show a strong increase in expressions of cardiac markers Nkx2.5, α-MHC,  
α-TM, and GATA4 upon initiation of differentiation. CVPC clone A5 and H3 already 
expressed these markers at low levels in the undifferentiated state, though expression 
was higher in clone H3 than in A5. Therefore expression levels of myocardial markers 
seem to vary between CVPC clones. Expression of myocardial markers in the 
undifferentiated state is an indicator for the commitment of CVPCs to the cardiac 
lineage. 
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Figure 14 Expression of myocardial genes in differentiated (d17) and undifferentiated (d0) CVPCs. RT-PCR 
analysis. GAPDH was used to balance cDNA amount. Myocardial markers are already expressed in the 
undifferentiated state of CVPCs. Differences between CVPC clones can be observed, clone H3 expresses myocardial 
markers at higher levels than clone A5. 
4.1.4.3 Mesodermal genes 
The heart is developed from mesoderm. Therefore we tested for an early marker for all 
mesoderm types (Brachyury) and marker for heart precursor cells (Mesp1) 
Mesp1 (mesoderm posterior 1) is expressed in the early mesoderm which gives rise to 
the extraembryonic and cranial-cardiac mesoderm. It is the earliest marker expressed in 
the heart precursor cells. Mesp1 heterozygous mice show abnormal heart morphology. 
Mesp1-/- show a defect in migratory activity of mesodermal cells (Saga, 1998; Saga et 
al., 1996; Saga et al., 1999). Mesp1 is upregulated upon loss of multipotency and 
differentiation of CVPCs (Figure 15).  
Brachyury (T) is a DNA binding transcription factor. It is one of the key transcription 
factors in the differentiation and determination of mesoderm in vertebrates (Technau, 
2001). In Xenopus T is involved in differentiation of all mesoderm cell types, while in 
mouse mesoderm can form in the absence of T. In Brachyury null mice, posterior 
mesodermal cells fail to migrate from the tailbud to the primitive streak leading to a 
failure of the axis to elongate. T/T mutant mESCs are less efficient in leaving the streak 
than wildtype mESCs after injection into wildtype host blastocysts (Wilson and 
Beddington, 1997; Wilson et al., 1995). Brachyury is expressed in the undifferentiated 
state and is downregulated upon initiation of differentiation. 
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Figure 15 mRNA expression of mesodermal genes during CVPC differentiation. RT-PCR analysis. GAPDH was 
used to balance cDNA amount. Mesoderm marker Brachyury is expressed in undifferentiated state of CVPCs but is 
absent in differentiating CVPCs. MEF2c, the earliest marker of heart precursors cells is strongly upregulated after 
induction of differentiation and is only weakly expressed in undifferentiated state.  
4.1.4.4 Receptor genes 
We already showed that CVPCs express certain receptors in the undifferentiated state. 
This suggested that CPVCS are sensitive to Activin, LIF, BMP, and TGF-β signaling. 
We wanted to test if this competence is lost after differentiation by downregulation of 
receptor expression or, in contrary, if receptor expression is upregulated. The latter 
might indicate an importance of that signaling cascade during development. 
Expression of Activin receptor ALK4 was not altered during differentiation of CVPCs. 
However, it is notable that the basic expression seems to vary between CVPC clones 
(Figure 16). BMP2 receptor ALK3 is strongly upregulated in differentiating CVPCs. 
This might indicate an important role of BMP signaling during cardiomyogenesis.  
ILK (integrin linked kinase) is important for SPARC mediated signaling. ILK is not a 
transmembrane receptor but is predominantly located on the cytoplasmic side of the 
plasma membrane and can interact with specific integrins. ILK can for example 
phosphorylate GSK3β and thereby influence the Wnt Pathway (Weaver et al., 2008). In 
CVPCs ILK expression was strongly upregulated upon differentiation (Figure 16). 
These results suggest an importance of BMP signaling mediated by receptor ALK3 
during CVPC differentiation. Furthermore signaling trough ILK seems to play an 
important role and might directly affect Wnt signaling. 
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Figure 16 mRNA expression of signal receptors in CVPCs. CVPC clones A5 and H3 were tested for mRNA 
expression levels of receptors with RT-PCR. Expression of Activin receptors ALK4 is not altered during 
differentiation, while ALK3 and ILK are both upregulated during differentiation. 
4.2 Characterization of Cardiovascular Progenitor Cells 
We wanted to characterize murine CVPCs and investigate the similarities and 
differences between CVPCs and mESCs. We used mESC clone AB2.2 as the basis for 
comparison. 
4.2.1 Murine embryonic stem cells AB2.2 
4.2.1.1 Growth on SNL 76/7 feeder layers 
Murine ESC strain AB2.2 was cultured on SNL76/7 feeder layers secreting Leukemia 
Inhibitory Factor (LIF). LIF is known to be sufficient to maintain self-renewal and 
proliferation of mESCs (Niwa et al., 1998; Raz et al., 1999; Williams et al., 1988). 
mESCs AB2.2 showed tight cell-cell interactions and dense colony formation. Colonies 
had smooth borders. Differentiation to endothelial cells at the rim of these colonies did 
not take place (Figure 17). Cell clusters were easily distinguishable one day after 
splitting but started blending in with the feeder layers upon an increase in cell number. 
 
Figure 17 CVPC and mESC morphology. CVPC clones A5 and H3 and mESC clone AB2.2 were grown on feeder 
layers. White arrowheads indicate undifferentiated CVPCs. White arrow marks undifferentiated ESCs. CVPC 
colonies are surrounded by differentiated endothelial cells (red arrow). Orange arrows represent feeder cells. mESC 
AB2.2 form tighter colonies, individual cells cannot be distinguished (bar=100µm). 
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4.2.1.2 Growth on gelatin coated plates 
In order to induce differentiation, murine ESCs AB2.2 were replated from feeder layers 
onto gelatin coated 24 well-culture dishes at very low cell density (2-3x104 cells/well).  
mESCs AB2.2 tended to aggregate upon transfer onto gelatin coated plates. Cell 
contacts within colonies were as tight as on feeder layers. Single mESCs AB2.2 were 
able to form new colonies within three days. Enlarged, differentiated cells started to 
appear at rims of cell colonies. By day 13 of differentiation colonies branched out 
forming tree like structures (Figure 18). 
 
Figure 18 mESC differentiation on gelatin coated plates. mESC AB2.2 on day 4 (A) and day 13 (B) of 
differentiation. Colony formation is seen in (A), enlarged cells formed in gaps between colonies (white arrow). After 
13 days former individual colonies were interconnected by branch like structures (bar=100µm (A), bar=300µm (B)). 
4.2.2 Murine Cardiovascular Progenitor Cells 
Eleven clones of Cardiovascular Progenitor cells were isolated from N1-2 neoR mice. 
The clones were termed A3, A5, B3, B5, C3, D3, D5, E3, F3, G3, and H3 (Wiedner, 
2008). 
Since co-culture of mESCs AB2.2 with LIF-secreting feeder layers is essential for the 
maintenance of self-renewal, we hoped the same held true for murine CVPCs. So far, 
we were able to culture CVPCs up to passage 68 on SNL76/7 feeder cell layers without 
a detectable loss of multipotency. 
4.2.2.1 Growth on SNL76/7 feeder layers 
CVPCs grown on feeder layers appeared increased in size compared to mESCs AB2.2. 
CVPCs within a colony were surrounded by a halo when observed under a light 
microscope, while mESCs were not. Therefore, individual CVPCs within a cell colony 
could be distinguished (Figure 17).  
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Enlarged CVPCs were found in the gaps between colonies the day after splitting and the 
number increased thereafter. To monitor the number of enlarged cells we chose CVPC 
clone A5.  
Within 2 passages, consistent with a 6 day time period, the number of enlarged cells 
formed by CVPC clone A5 did not increase significantly (from 4.6% to 4.8%). 
Although a percentage of these enlarged cells was transferred upon replating on new 
feeder layers, these cells did not seem to be able to adhere as well as undifferentiated 
CVPCs and often settled on top of CVPC colonies. As enlarged cells appeared in gaps 
between CVPC colonies without the requirement of other enlarged cells being present, 
we assumed that the newly formed enlarged endothelial cells originated from 
undifferentiated CVPCs rather than through cell division of replated enlarged cells. The 
number of differentiated cells developing under a 3T3 protocol remained stable (Table 
2). This indicated that these cells had either a lower survival rate, could not attach to 
feeder layers, or had a significantly decreased growth rate. It took approximately 2 days 
before the number of enlarged cells started increasing. This means that a 2T2 protocol 
reduced the formation of enlarged cells but could not inhibit it entirely. The 2T2 
protocol potentiated the selection towards fast replicating CVPCs. 
We reasoned that 5% differentiation was less influential on further experiments than a 
constant selection towards fast replicating cells and therefore we set the 3T3 protocol as 
standard for CVPC culture. 
Number of enlarged 
cells/visual field 
Total number of 
cells/visual field 
Percentage of enlarged 
cells/visual field 
A5p11 A5p13 A5p11 A5p13 A5p11 A5p13 
6 2 151 116 3.8% 1.7% 
12 8 197 169 6.1% 4.7% 
3 14 111 173 2.7% 8.1% 
 15  263  5.7% 
 5  189  2.6% 
21 44 459 910 4.6% 4.8% 
Table 2 Differentiation of CVPC clone A5 under regular culture conditions. CVPCs were split 1:3 and 
sedimentation was monitored with a Olympus CK2 Phase Contrast microscope. The total cell number per visual field 
and the number of enlarged cells per visual field were determined. The mean percentage of enlarged cells was 
calculated. 
4.2.2.2 Growth on gelatin coated plates 
CVPCs were transferred from feeder layers onto gelatin coated plates and left to 
differentiate in the absence of LIF. The cell density was chosen so that almost all cells 
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adhered individually. Cells did not form tight colonies as observed when grown on 
feeder layers (Figure 19A) but formed loose cell-cell contacts (Figure 19B). Individual 
cells could be distinguished. Cell morphology changed from a round shape, when 
cultured on feeder layers, to an angular shape (Figure 19A+B).  
 
Figure 19 Growth on feeder layers (A) and gelatin (B). CVPCs show tight colony formation upon growth on 
feeder layers but very loose cell-cell interaction when grown on gelatin coated dishes. Individual cells are much 
easier to distinguish when cultured on gelatin (B). Cells exhibit round cell morphology on feeder layers (A) and 
angular cell morphology on gelatin (B) (bar=100µm). 
4.2.3 Growth rate 
4.2.3.1 Growth rate on feeder layers 
We wanted to investigate whether the growth rate of CVPCs differed from the growth 
rate of mESC line AB2.2 when grown on LIF secreting SNL 76/7 feeder layers.  
CVPC clone A5 was grown on SNL76/7 feeder layers. 150 000 cells were seeded and 
the increase in cell number was monitored on a three day interval. After counting, 150 
000 cells were replated on new feeder layers. This procedure was continued over a 22 
day time period. Natural logarithm of cumulative cell number was calculated. The 
doubling time of mESCs AB2.2 on feeder layers was reported to be 17.3h±6.4h under 
similar culture conditions (Lauss et al., 2005). 
When grown on SNL76/7 feeder layers, the growth rate of CVPC clone A5 remained 
constant over the entire 22 day time period. The doubling time of clone A5 under these 
conditions was 18.7h±1.2h (Figure 20, Table 3). 
These results revealed that the doubling time of CVPC clone A5 was comparable to the 
doubling time of mESCs AB2.2. 
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Figure 20 Growth curve of CVPC clone A5. Cells were grown on feeder layers expressing LIF (termed SNL). 
BMP2 and M-LIF were added at a concentration of 100ng/ml upon feeding every three days. 150 000 cells were 
seeded per 24 well and every three days cells were counted and the cell number was reduced to 150 000 cells. Natural 
logarithm of cumulative cell number was calculated.  
treatment Mean doubling time (h) Standard deviation 
mESC line AB2.2 17.3 6.4 
CVPC clone A5 18.7 1.2 
 
Table 3 Growth rate of CVPCs and mESCs. CVPCs were seeded at a density of 150 000 cells, after 3 days cell 
number was determined and 150 000 cells were replated on new feeder layers. Doubling time is mean of 5 
consecutive measurements over a 15 day time period. Doubling time and standard deviation of AB2.2 is according to 
Lauss et al. (2005). 
LIF produced by SNL76/7 feeder cells is essential for self-renewal of mESCs. We were 
interested if elevated levels of LIF could further enhance growth conditions of CVPCs 
compared to CVPCs grown on feeder layers (SNL). Growth rate was not influenced by 
the addition of M-LIF but stayed stable around 19 h per cell cycle. Furthermore, 
addition of Bone Morphogenetic Protein 2 (BMP2) alone or in combination did not 
affect growth rather of CVPCs on feeder layers (Table 4, Figure 20). 
BMP2 is known to induce the inhibitor of differentiation genes and we wanted to 
investigate if addition of BMP2 can prevent formation of enlarged cells in the presence 
of feeder layers. Cells supplied with BMP2 did not show a decrease in differentiation to 
endothelial cells (Figure 21).  
Increased amounts of BMP2 (100ng/ml) and M-LIF (100ng/ml) did not affect formation 
and morphology of CVPC colonies compared to untreated cells grown on feeder layers.  
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CVPC treatment Mean doubling time (h) Standard deviation 
SNL 18.7 1.3 
SNL+M-LIF 19.0 1.2 
SNL+BMP2 19.1 0.9 
SNL+BMP2+M-LIF 18.9 1.1 
 
Table 4 Doubling time of CVPC clone A5. CVPCs were grown on SNL76/7 LIF-secreting feeder layers (SNL).  
150 000 cells were seeded and treated as indicated (100ng/ml BMP2; 100ng/ml M-LIF). After three days cells were 
counted and 150 000 were transferred onto new feeder layers. Doubling time was calculated. Values are mean of five 
consecutive measurements over a 15 day time period.  
 
Figure 21 Influence of BMP2 and M-LIF on colony formation. 150 000 A5 CVPCs were seeded onto SNL76/7 
feeder layers. BMP2 (100ng/ml) and M-LIF (100ng/ml) were added as indicated. Addition of either of these factors 
did not effect cell morphology. CVPCs still exhibited colony formation and round cell shape. Addition of BMP2 
could not inhibit differentiation to endothelial cells in the gaps between colonies (bar=25µm) 
4.2.3.2 Growth rate on gelatin 
In the absence of LIF-secreting feeder layers, CVPCs started differentiating and formed 
cardiomyocytes, smooth muscle cells, and endothelial cells. This differentiation took 
place without the addition of external factors. The differentiation medium did not vary 
from growth medium. We wanted to test whether LIF alone is sufficient to maintain 
self-renewal and growth rate, or if other factors secreted by the SNL 76/7 feeder were 
essential. 
Doubling time of CVPCs grown on gelatin was increased from 19.4h±1.0 when treated 
with M-LIF to 26.2h±3.8 in the absence of LIF (Table 4, Table 5). Addition of BMP2 
alone could not maintain growth rate and doubling time was increased to 26.0h±2.6. In 
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comparison, addition of insect cell derived M-LIF could sufficiently keep doubling time 
(19.4±1.0) at nearly the same level as of cells grown on feeder layers (18.7h±1.3). 
Combined addition of BMP2 and M-LIF showed the same effect as M-LIF alone 
(Figure 22). Since BMP2 alone could not maintain growth rate, M-LIF appeared to be 
the critical factor. Therefore, M-LIF seems sufficient for maintenance of self-renewal of 
CVPCs in the absence of feeder layers (Table 4, Table 5). 
 
Figure 22 Growth curve of CVPC clone A5. CVPCs termed SNL were cultured on feeder layers. Cells termed 
control (untreated), M-LIF, BMP2, and BMP2+M-LIF were cultured on gelatin coated plates. 150 000 cells were 
seeded and counted every three days. After counting, the cell number was reduced to 150 000 and BMP2 (100ng/ml), 
M-LIF (100ng/ml) were added to cells as indicated. In the absence of LIF cell numbers steadily decreased. 
CVPC treatment Mean doubling time (h) Standard deviation 
control 26.2 3.8 
M-LIF 19.4 1.0 
BMP2 26 2.6 
BMP2+M-LIF 19.1 0.9 
 
Table 5 Doubling time of CVPC clone A5. CVPCs were grown on gelatin coated plates in the absence of feeder 
layers. 150 000 cells were seeded and treated as indicated (100ng/ml BMP2; 100ng/ml M-LIF). After three days cells 
were counted and 150 000 were replated on new feeder layers. Values are mean of five consecutive measurements. 
Cell morphology of untreated cells did not differ from M-LIF treated cells with the 
notable exception that cell fragments were frequently observed in the absence of M-LIF 
(Figure 23). Therefore, the decrease in growth rate shown in Table 5 might not be solely 
due to a decelerated cell cycle or a decreased self-renewal. Cells died in the absence of 
M-LIF. After more than 30 days of culture on gelatin coated plates in the absence of 
LIF, the cell number was significantly decreased and confluence could no longer be 
reached on a 3T3 protocol (<20% cell density, data not shown). As seen in Table 6, 
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after 7 days the cell number in the M-LIF treated well (5.0x106) was more than 60fold 
the cell number in the untreated well (8.1x104). Viability of the LIF treated cells was 
higher than 90%, whereas the viability of control was 68%. Viability of BMP2 treated 
cells (82.8%) was increased compared to untreated cells. Therefore, BMP2 could save 
cells from cell death in the absence of LIF to a certain degree. Although frequent cell 
death was observed in BMP2 treated wells cell number was 28.4 fold higher than in 
untreated wells but 2.2 fold lower than in LIF treated wells after 7 days (Figure 23). 
 
Figure 23 Growth of CVPC clone A5 on gelatin. CVPCs were treated with 100ng/ml BMP2 and/or 100ng/ml M-
LIF in the absence of feeder layers as indicated. Both in the control well and the BMP2 treated well dead cells were 
detected frequently (white arrows) while fragments of dead cells were almost absent in wells supplied with M-LIF 
(bar=50µm). 
CVPC treatment Cell number/well Viability (%) 
Growth on gelatin viable total  
Control 5.5x104 8.1x104 67.9 
+M-LIF 4.6x106 5.0x106 91.9 
+BMP2 1.9x106 2.3x106 82.8 
+BMP2+M-LIF 2.1x106 2.5x106 86.5 
 
Table 6 Viability of CVPCs grown on gelatin. Equal cell numbers were seeded (150 000) and cells were cultured 
for 7 days under M-LIF, BMP2, M-LIF+BMP2 (100ng/ml) treatment of left untreated. Cell number was counted with 
a CASY counter. 
4.2.3.3 Transfer from gelatin coated plates to feeder layers 
Morphology of CVPCs instantly changed from round to angular shape upon transfer 
from feeder layers onto gelatin coated plates. This morphology change was not 
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influenced by the treatment with BMP2 or M-LIF. We were interested if this 
morphology change was reversible.  
CVPC A5p12 grown on gelatin appeared angular and wide spread, independent of 
treatment with BMP2 and/or M-LIF (Figure 23). While not forming tight colonies, cells 
did aggregate. After two passages (5 days) on gelatin 4.5x105 cells were replated on 
feeder layers and treatment with M-LIF and/or BMP2 was stopped. Cells immediately 
adapted round cell shape similar to the cell shape they displayed from passage 1-11. 
Cells formed dense colonies, however, individual cells could be distinguished (Figure 
24). Cell shape was round and no longer angular. Therefore, cell shape shift was 
reversible and cell shape adapted depending on matrix. Overall cell size appeared 
slightly increased. Single enlarged cells were visible (Figure 24). No difference in cell 
shape or size was detected between cells previously treated with BMP2 and/or M-LIF. 
Untreated cells showed a slightly increased number of enlarged cells. 
 
Figure 24 CVPC clone A5 previously cultured on gelatin coated plates. CVPCs were cultured on gelatin coated 
plates for 5 days, splitting took place on day 2 of culture. CVPCs were treated with 100ng/ml BMP2 or 100ng/ml M-
LIF in the absence of feeder layers, as indicated. After 5 days 450 000 cells were transferred back onto feeder layers 
and pictures were taken the following day. White arrows mark enlarged cells. Untreated cells grown on feeder layers 
are termed SNL (bar=100µm). 
4.2.4 SPARC secretion  
Parietal endoderm-secreted SPARC was found to positively influence cardiomyogenesis 
in mESCs (Stary et al., 2005). Our primary goal was the enhancement of 
cardiomyogenesis in CVPCs. Therefore, we wanted to test the effect of recombinant 
SPARC on CVPCs. We performed Dot Blot analysis in order to determine whether 
CVPCs express and secret SPARC. 
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The supernatant of CVPC clone A5 was taken 2 h and 24 h after medium change in 
order to see if SPARC secretion was a fast or slow process. Figure 25 shows that 
SPARC was already secreted at a high level 2 h post medium change and was only 
slightly more enriched in the supernatant during the next 22h.  
Parietal Endoderm (PE) is known to secret SPARC at high levels. Therefore, we 
compared PE supernatant to CVPC supernatant. SPARC levels were approximately 
equal. Using known quantities of recombinant SPARC as reference, the SPARC 
secretion of CVPC clone A5 was determined to be approximately 2 µg/ml under regular 
culture conditions in 70% confluent wells (Figure 25). 
 
Figure 25 Dot Blot analysis of supernatant. Recombinant SPARC (2 µg/ml, 1 µg/ml, 0.5 µg/ml, and 0.25 µg/ml), 
supernatant of CVPC clone A5 2 hours and 24 h after feeding and supernatant of parietal endoderm were applied on 
nitrocellulose membrane, respectively. Supernatants were diluted 1:1, 1:2, 1:4, and 1:8 in M15Hy. 1st antibody used 
was anti-SPARC (1:300) and 2nd antibody was anti-rabbit HRP (1:20 000).  
Dot Blot analysis showed secretion of SPARC by CVPCs. Further, we visualized 
intracellular SPARC in CVPC clone A5 by immunofluorescence. Therefore, in CVPCs 
SPARC protein can be found both in the intracellular and the secreted form. This stands 
in contrast to mESC cell line AB2.2 which was found to express SPARC on mRNA 
level but does not secrete SPARC protein (Stary et al., 2005) 
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Figure 26 Immunofluorescence of SPARC. SPARC is distributed throughout the cytoplasma of CVPC clone A5. 
SPARC was detected by anti-SPARC antibodies and with texas red-labeled secondary antibodies. 
4.3 Differentiation 
4.3.1 Monolayer model system 
Transfer of mESCs AB2.2 to gelatin coated plates resulted in differentiation, but 
beating cardiomyocytes were never observed. Upon transfer of CVPCs onto gelatin 
coated plates they started differentiating into the three cell types of the murine heart, 
namely cardiomyocytes, smooth muscle cells, and endothelial cells (Figure 27).  
 
Figure 27 Immunofluorescence labeling of CVPC clone A5. Differentiated CVPCs were separated by 
trypsinization and fixated on slides. Cardiomyocytes were visualized with anti-cardiac Troponin T antibodies (A). 
CVPCs were left to differentiate and once smooth muscle contraction was observed, stained with anti-smooth muscle 
actin antibodies (B). 
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Cardiomyocyte formation of CVPC was chaotic and the number varied highly between 
experiments. Smooth muscle cells formed in close proximity to cardiomyocytes and 
eventually displaced them. Smooth muscle cell formation was very limited and not 
observed at all times. Since we were not further interested in smooth muscle cell 
formation but in enhancement of cardiomyogenesis, we set our primary goal in the 
refinement of differentiation conditions in order to achieve a higher yield of 
cardiomyocytes.  
4.3.1.1 Optimization of differentiation conditions 
4.3.1.1.1 Choice of culture plates 
We first performed differentiation experiments in 6 well plates at a cell density of  
110 000 or 150 000, respectively. As seen in Figure 28, only small areas of the 6 well 
plates showed signs of differentiation, most of the beating clusters were found around 
the edges of the culture dishes. Beating cardiomyocyte clusters were rarely observed in 
the center of the culture dishes. Endothelium formation was predominant. The number 
of beating clusters was extremely low under the applied differentiation conditions 
(Figure 29). Since clone A5 seemed the most promising in terms of cardiomyocyte 
formation, we selected it for further analysis along with clone H3 and G3 which showed 
intermediate and very low number of cardiomyocytes, respectively. Even though 
cardiomyocyte formation was not abundant, all eleven clones proved positive for it, 
whilst mESC cell line AB2.2 did not form cardiomyocytes in this or any of the 
following experiments under monolayer differentiation conditions.  
Since we saw most cardiomyocyte formation at the rim of the culture dishes we 
switched to 24 wells, hoping we could control conditions better in smaller areas. 
 
Figure 28 CVPC monolayer differentiation. CVPC clone A5p24 is shown on day 11 after seeding. Dark areas 
represent areas likely to form cardiomyocytes, areas in between are covered in endothelium (bar=300µm). 
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Figure 29 Monolayer differentiation. Total number of beating cardiomyocyte clusters observed over a ten day time 
period are shown. 300 000 cells were cultured on gelatin coated 24 well for four days prior to seeding onto 6 well 
plates. 110 000 and 150 000 cells were seeded onto gelatin coated 6 well plates, respectively, and fed every other day, 
as needed. mESC cell line AB2.2 did not show cardiomyocyte formation.  
4.3.1.1.2 Cell number 
Seeding cell number was a critical factor as cell-cell contact between CVPCs influenced 
their differentiation behavior. When the cell number was too high, plates grew over-
confluent and cells remained mainly undifferentiated; when the cell number was chosen 
too low the plates never grew confluent and differentiation hardly took place (Figure 
30).  
Cells were seeded onto gelatin coated 24 well plates on day zero and clusters of beating 
cardiomyocytes were observed by day 18 (Figure 30). The number of beating clusters 
was significantly enhanced compared to our preliminary experiments performed on 6 
well plates. In the 6 well system we detected less cardiomyocytes within 10 days than in 
the 24 well system on 1 day (Figure 29, Figure 30). Beating cardiomyocyte clusters 
were no longer restricted to the edges of culture wells but were evenly distributed. Cell 
numbers between 16 000 and 30 000 cells turned out to be the most promising and were 
adapted for further experiments.  
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Figure 30 Monolayer differentiation. Indicated cell numbers of CVPC clone A5p15 were seeded onto gelatin 
coated 24 wells and left to differentiate. Partial (50%) medium replacement took place daily starting day 10. First 
beating cardiomyocyte clusters were observed on day 18 of differentiation. Wells with the lowest starting number 
developed the highest number of beating cardiomyocytes. 
4.3.1.1.3 Feeding protocol 
Higher rates of beating cardiomyocytes were achieved when the medium was only 
changed partially (data not shown). In order to supply cells with enough nutrients we 
decided on replacing approximately half of the growth medium every 24h. The first day 
of medium change depended on the number of seeded cells but was usually between 
day 3 and 6. 
Figure 31 shows the influence of medium change on differentiation. Feeding started on 
day 5 instead of day 10 (Figure 30, Figure 31), therefore enough nutrients were supplied 
at all times. A tenfold increase in cardiomyocyte formation was observed when feeding 
protocol was altered. Partial medium change was continued from then on and 
percentage of changed growth medium increased every other day as needed. 
While CVPC clone A5 needed a higher starting number of around 30 000 cells per 24 
well in order to form a maximum of cardiomyocyte clusters (>6000), the same cell 
number produced much fewer cardiomyocyte clusters (<1000) in clone H3. CVPC 
clone H3 tended to stay undifferentiated when cell numbers over 20 000cells /24 wells 
were used. When H3 was seeded at a density of 30 000 cells even after 43 days of 
differentiation these cells still appeared almost entirely undifferentiated (Figure 32). 
Therefore, the two CVPC clones A5 and H3 required a different seeding cell number in 
order to produce a maximum of cardiomyocytes.  
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Figure 31 Monolayer Differentiation of CVPC clones A5 and H3. Cells were seeded at 10 000, 20 000, and  
30 000 cells per 24 well in 1ml of growth medium, 1 ml of growth medium was added to 20 000 and 30 000 wells on 
day 5 and to 10 000 on day 7. 1 ml of growth medium was changed daily thereafter. CVPC clone H3 required lower 
cells numbers to form a maximum of cardiomyocytes, while clone A5 required higher numbers. 
 
Figure 32 Monolayer Differentiation of CVPC clone H3. CVPC clone H3 was seeded at a density of  
30 000 cells/24 well and left to differentiate, medium change took place daily after day 6, on day 5 one ml of growth 
medium was added. After 43 days of differentiation cells still appear undifferentiated and only low number of 
cardiomyocytes had formed (bar=300µm). 
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4.3.1.2 Enhancing cardiomyogenesis 
Our main goal was to find ways to direct differentiation towards cardiomyocyte 
formation and away from smooth muscle and endothelium formation.  
Since we already determined that M-LIF was sufficient for self-renewal we decided to 
culture CVPC clone A5 on gelatin coated plates in the presence of M-LIF. We reasoned 
that this limits influence of other substances secreted by the feeder cells on CVPCs. 
Further, we treated A5 with BMP2 and BMP2 combined with M-LIF, respectively. As 
control we continued to grow CVPC clone A5 on feeder layers. After 30 days of culture 
under the above described conditions on a 3T3 protocol we let cells differentiate.  
Cells treated with BMP2 showed decreased cell survival during the 30 day treatment 
period (Figure 22). Upon differentiation BMP2 treated cells showed delayed formation 
and drastically reduced number of cardiomyocyte clusters (Figure 33). Only few and 
very small areas showed beating cardiomyocytes.  
Cells that were treated with M-LIF and not exposed to any other substances secreted by 
feeder cells, formed twice the number of cardiomyocytes compared to CVPCs cultured 
on feeder layers. Onset of cardiomyogenesis was enhanced by 2 days. M-LIF treated A5 
formed cardiomyocytes to an extent we did not observe before in the monolayer system 
(Figure 33). 
Pre-conditioning CVPCs with a combined treatment of BMP2 and M-LIF for 30 days 
before differentiation resulted in an onset of cardiomyogenesis and a number of 
cardiomyocytes comparable to control level. 
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Figure 33 Maximum beating cardiomyocyte clusters of CVPC clone A5. A5 cells were seeded on gelatin coated 
24 wells and treated with 0.1 µg/ml M-LIF, 0.1 µg/ml BMP2, or both BMP2 and M-LIF, respectively. Splitting 
occurred once cells were at least 70% confluent. After 31 days of treatment, 30 000 cells were seeded on gelatin 
coated 24 wells and partial medium change took place whenever necessary. Cells termed “Feeder” were cultured on 
feeder layers previous to seeding (30 000/gelatin-coated 24 well). Number of beating clusters was counted daily. 
Average of the four consecutive days with the highest number of beating clusters was calculated. Time period of 
maximum cardiomyocyte development is indicated on x-axis. 30 days of BMP2 treatment prior to seeding delayed 
peak of beating clusters by 5 days and led to 52-fold decrease of beating cluster development compared to untreated 
cells (Feeder). LIF treatment resulted in a more than 2-fold increase of beating clusters and accelerated development 
by 2 days.  
4.3.2 Cardiac Bodies 
We could not sufficiently control monolayer differentiation and the degree of 
cardiomyogenesis varied between experiments. From mESC research we were familiar 
with the Embryoid Body (EB) system. Even though we did not expect CVPCs to be 
able to mimic embryogenic development in a way EBs do, we reasoned that aggregation 
of CVPCs without attachment to a culture dish might resemble in vivo conditions better.  
Cardiac Bodies (CBs) were generated with CVPC clone A5. CBs were not fed daily but 
according to our standard protocol for EBs. CBs are larger in size and therefore more 
nutrients were required than supplied by the standard protocol. Beating intensity slowed 
down when nutrients were too low. Therefore, counted values of feeding days were not 
incorporated into the statistics but are shown in the appendix. 
Figure 34 shows the percentage of CBs with beating cardiomyocytes on a daily basis. 
First beating cardiomyocytes were observed on day 11 and percentage of CBs with 
beating cardiomyocytes increased rapidly thereafter. By day 17 all CBs had formed 
beating cardiomyocytes. Onset of cardiomyogenesis in the monolayer system occurred 
on day 17 (Figure 31), 6 days later than in CBs.  
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Figure 34 Cardiomyogenesis in CBs. A5p47 (4.4x104 cells/ml). Data is mean of 6 control wells. First beating 
cardiomyocytes were observed on day 11 of differentiation. By day 17 100% of CBs had formed beating 
cardiomyocytes. Values of feeding days were not included in figure but are given in the appendix (Table 11). 
From preliminary experiments we knew that EBs form a horseshoe like structure shortly 
after attachment to culture plates and right before first cardiomyocytes appear. This 
structure was mostly absent in CBs. Sometimes horseshoe like structures could be 
detected but developed most likely by chance. CBs started spreading out after 
attachment (Figure 35) and increased in size faster than EBs (not shown). 
CBs did not form first cardiomyocytes in one specific location as EBs do, in most cases 
several small beating clusters appeared at once. Around 5 days after first clusters could 
be observed, cardiomyocytes were spread out all over the CBs, often representing more 
than 50% of the CB area. Large areas of the CB contracted rhythmically, either in the 
same rhythm or a chain reaction. Cardiomyocytes of EBs are usually limited to the 
outskirts of EBs. 
Smooth muscle cells were not observed in all CBs. Smooth muscle formation was 
triggered by unknown factors just like in the monolayer system. Within one culture 
dish, containing more than 50 CBs, only some CBs formed contracting smooth muscle 
cells while others did not. This is surprising since these CBs were exposed to the same 
growth medium. Percentage of CBs forming smooth muscle cells was always very low 
(<15%). Since smooth muscle formation was not our primary interest, we did not 
investigate this any further. 
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Figure 35 CB on day 7 of differentiation. CB 2 days after adhesion to culture plates (A). Cells around the edges of 
the CB start spreading out (B) (bar=300µm). 
4.3.2.1 Influence of BMP2 and M-LIF on cardiomyogenesis in CBs 
Behfar et al. (2002) showed that treatment of mESCs with BMP2 for 24 h prior to EB 
formation resulted in a more than twofold increase of contracting areas compared to 
EBs from untreated mESCs. 
Rajasingh et al., 2007 reported that mESCs treated with a combination of LIF and 
BMP2 before injection into mice after an induced myocardial infarction showed typical 
cardiomyocyte morphology and striation pattern after 28 days 
CBs were generated from CVPC clone A5. CBs were treated with M-LIF (100 ng/ml), 
BMP2 (100 ng/ml), anti-BMP2/4 antibodies (500 µg/ml), anti-LIF antibodies (1 µg/ml), 
and BMP2 and M-LIF combined, respectively. Substances were added once at 
beginning of each treatment period, no medium change took place during the treatment 
periods. Treatment periods were day 0-4.7, day 4.7-7, day 7-10, and day 10-13, 
respectively. Six control plates were left untreated.  
4.3.2.1.1 Leukemia Inhibitory factor 
Addition of M-LIF on day 0 resulted in the formation of CBs that were decreased in 
size and, upon attachement, cell spreading was severly hamperd (Figure 36). First 
beating cardiomyocytes were observed on day 17 with a six day delay compared to 
control. By day 21, percentage of CBs with beating cardiomyocytes had still not 
reached 100% (Figure 37A). 
M-LIF did not affect time of cardiomyocyte development or number of formed 
cardiomyocytes when added on day 4.7 (Figure 37). When supplied with M-LIF on day 
7 or day 10 cardiomyocyte formation was delayed by 2 days (Figure 37C+ D) and, as 
seen in Figure 38, number of cardiomyocytes per CB was reduced. 
48 
 
Anit-LIF antibodies enhanced cardiomyogenesis when added on day 0 (Figure 37) and 
strongly increased the number of beating cardiomyocytes per CB when added on day 0, 
4.7 or 10, respectively (Figure 38). Together, addition of anti-LIF antibodies on day 0 
enhanced cardiomyogenesis, while addition of LIF delayed it. 
When M-LIF and BMP2 were combined, effect of M-LIF was dominant (Figure 38, 
data not shown). 
 
Figure 36 CBs on day 4.7 of development. CBs were treated with BMP2 (100ng/ml) or M-LIF (100ng/ml) between 
day 0 and day 4.7. M-LIF treated CBs showed decreased cell spreading and appeared undifferentiated in the center. 
Cardiomyogenesis was delayed. Morphology of BMP2 treated CBs cannot be distinguished from control 
(bar=300µm). 
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Figure 37 Influence of LIF on CB Development. Addition of M-LIF (100ng/ml) on day 0 (A) resulted in CBs 
severely reduced in size and delayed cardiomyogenesis, while addition on day 4.7 (B) showed no effect. Addition on 
day 7 (C) and 10 (D) cardiomyogenesis was delayed by 2 days. Addition of anti-LIF antibodies (1 µg/ml) had a 
slightly positive effect on day 0 suggesting that an inhibition of LIF signaling is beneficial during the early stages of 
cardiomyogenesis. 
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Figure 38 Beating intensity of CBs. Areas of beating cardiomyocytes per CB were quantified daily on a scale from 
0 (no activity) to 6 (>70% of the area contracting). Values of day 0-20 were added and set relative to control. Data 
can be seen in appendix (Table 12). BMP2 treatment enhanced formation of cardiomyocytes per CBs strongly. 
Addition of anti-BMP2 antibodies slightly reduced number of cardiomyocyte clusters per CB. M-LIF had a negative 
effect on the number of formed cardiomyocytes. M-LIF and BMP2 combined had an effect similar to M-LIF 
treatment. Anti M-LIF antibodies increased the number of cardiomyocytes.  
4.3.2.1.2 Bone Morphogenetic Protein 2 
Addition of BMP2 had a positive effect on cardiomyogenesis at every tested time point 
of CB development. Not only did it enhance first cardiomyocyte appearance but it also 
led to a highly increased number of beating cardiomyocytes per CB (Figure 38).  
BMP2 had the strongest effect on cardiomyogenesis when added on day 4.7 and day 7, 
respectively. In both cases 100% of CBs had formed beating cardiomyocyte clusters by 
day 13, 4 days earlier than in controls (Figure 39). As seen in Figure 38, the number of 
beating cardiomyocytes per CB was strongly increased in all cases.  
Interestingly, anti-BMP2/4 antibodies only had a slight negative effect on the onset of 
cardiomyogenesis when added on day 0, 7, or 10 but had no effect when added on day 
4.7 (Figure 39). The number of cardiomyocytes per CB was not influenced by anti-
BMP2/4 antibodies when added on day 0 or 4.7 and was slightly attenuated when added 
on day 7 or 10 (Figure 38).  
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Figure 39 Influence of BMP2 on CB Development. BMP2 (100ng/ml) enhanced cardiomyogenesis when added on 
day 0 (A), 4.7 (B) or day 7 (C), while addition of BMP2/4 antibodies negatively influences cardiomyogenesis on 
these days. On day 10 BMP and BMP antibodies had no effect (D).  
4.3.2.1.3 Influence of M-LIF and BMP2 on phosphorylation levels in CBs 
We wanted to investigate which pathways are upregulated during CB development. 
Protein Lysats of CBs treated with BMP2, M-LIF, anti-LIF antibodies, and control were 
prepared. Cell lysis took place at the end of each treatment period (d4.7, d7, d10, d13 
respectively). Cell number on day 4.7 was not high enough to balance protein level of 
Western Blots.  
Phosphorylation of Stat3 was highly elevated in all CBs treated with M-LIF relative to 
overall Stat3 levels. CBs treated with anti-LIF antibodies showed a down regulation of 
pStat3 during treatment periods of d4.7-7 and d7-10. pStat3 levels were not altered 
between control and BMP2 treated CBs (Figure 40). 
0
20
40
60
80
100
9 12 15 18 21p
er
ce
nt
ag
e 
of
 b
ea
tin
g 
C
Bs
time (d)
A         treatment d0-d4.7
0
20
40
60
80
100
9 12 15 18 21p
er
ce
nt
ag
e 
of
 b
ea
tin
g 
C
Bs
time (d)
B         treatment d4.7-d7
0
20
40
60
80
100
9 12 15 18 21
pe
rc
en
ta
ge
 o
f b
ea
tin
g 
C
Bs
time (d)
C         treatment d7-d10
0
20
40
60
80
100
9 12 15 18 21
pe
rc
en
ta
ge
 o
f b
ea
tin
g 
C
Bs
time (d)
D       treatment d10-d13
52 
 
Different treatment of CBs did not influence phosphorylation of Erk1/2. pERK1/2 was 
upregulated in all CBs by day 13 (Figure 40). 
pSmad1/5/8 was upregulated in CBs treated with BMP2 during a time period between 
d4.7-7, d7-10, and d10-13. No activation was detectable on day 4.7 when CBs were 
treated between d0-4.7.  
 
Figure 40 Western Blot of CB Lysats. CBs were treated with BMP2 (100ng/ml), M-LIF (100ng/ml) and anti-M-LIF 
antibodies (1 µg/ml) from day 0-4.7, 4.7-7, 7-10, and 10-13, respectively. At the end of each treatment period, 
proteins were isolated. Western Blot analysis with Stat3, pStat3, pSmad1/5/8, pErk1/2 and GAPDH were performed. 
pStat3 is increased upon M-LIF treatment. BMP2 induces pSmad1/5/8 signaling. pErk2 is not influenced by 
treatment.  
This suggests a role of BMP and MAPK signaling during CB development. Stat3 signaling 
seems to remain relatively stable during cardiomyogenesis.  
4.3.2.2 GSK3 inhibitor Chir99021 
In previous experiments we saw a positive effect of SPARC on cardiomyogenesis of 
CVPC clone H3 (H.Auner, unpublished data). Since SPARC was shown to signal via 
ILK, which in turn controls GSK3 activity, we had reason to believe that SPARC might 
signal through the Wnt pathway by affecting GSK3 activity. We therefore wanted to 
test if Chir99021, an inhibitor of GSK3, can mimic SPARC effect and enhance the 
number of cardiomyocytes. Since our preliminary experiments with Chir99021 were 
performed using CVPC clone H3, we continued with the same clone. 
Cells were seeded onto gelatin coated plates to induce differentiation and were treated 
with Chir99021 (1.399 µg/ml 1:1, 1:2 1:10, 1:50, 1:70, 1:100, 1:150) daily. After 24 
days of treatment only dilutions higher than 1:50 had formed beating cardiomyocytes 
but the number was drastically reduced compared to control levels (data not shown). 
Since cells looked mainly undifferentiated (Figure 41A), we replated cells treated with 
1.399 µg/ml back onto feeder layers on day 20 of treatment. After three days cell 
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morphology (Figure 41B) was indistinguishable from untreated control cells grown on 
LIF-secreting feeder layers. In order to test whether these cells still had the potential to 
form cardiomyocytes we made CBs. In Figure 41C a CB is shown on day 4.5, 
morphology is round and shows no noticeable alterations. A CB after attachment on day 
7 is shown in Figure 41D. CBs showed first beating cardiomyocytes on day 10 and by 
day 18 100% of CBs had formed beating cardiomyocytes. This means that the 
multipotency of CVPC potential was not decreased after 20 days of culture in the 
presence of GSK3 inhibitor Chir99021. Continuous Chir99021 treatment and 
consequential inactivation of GSK3 could not induce cardiomyogenesis but rather 
blocked it. Whether a time restricted inactivation of Chir99021 enhances 
cardiomyogenesis remains to be determined. 
 
Figure 41 Chir99021 treated CVPCs. CVPC clone H3 after 20 days of treatment with 1.399 µg/ml Chir99021 on 
gelatin (A). Cells three days post transfer of cells from (A) onto feeder layers are shown in (B). Normal colony 
formation took place. Cells could not be distinguished from control wells grown on feeder layers. Cells from (B) 
were used to create CBs. (C) shows CB on day 4.5, (D) on day 7 (bar=200µm (A), bar=100µm (B), bar=300µm 
(C,D)). 
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Figure 42 Cardiomyocyte formation of Chir99021 treated cells. CBs were generated from CVPC clone H3. Cells 
were previously treated with 1.399 µg/ml for 20 days and 0.1399 µg/ml for 11 days, respectively. All CBs were able 
to form beating cardiomyocytes. 
4.4 Transfections 
Nkx2.5 is an early marker for cardiomyogenesis. Therefore, we wanted to use Nkx2.5 
expression as a reporter system for differentiation towards the cardiac lineage in 
CVPCs. We used a Plasmid containing a Luciferase reporter gene under the control of 
the promoter region of the Nkx2.5 locus (NKE24).  
4.4.1 Establishment of a transfection protocol 
We first had to establish a transfection protocol for CVPCs since we had not performed 
transfections in these cells before. Therefore, we used the pGM3-EGFP-Vimentin 
plasmid so we could visually detect GFP expression by a Zeiss Axio Cam MR Plus 
without performing luciferase assays.  
4.4.1.1 Cell density 
According to supplier information cells should be between 90-95% confluent on day of 
transfection with Lipofectamine 2000, and a cell number of 0.5-2x105 was suggested. 
Since CVPCs are much smaller than fibroblasts we chose 1x105, 5x105, 1x106, and 
5x106 cells. Only 5x106 cells reached 95% cell density by time point of transfection. 
When 1x105 cells were seeded, wells were still not confluent 48h after transfection, 
while all the other wells were. Although GFP expression was detectable in all test 
transfections, the strongest GFP expression was detectable when the smallest starting 
cell number was chosen. GFP expression and detection was impeded when cell number 
was too high, lower cell numbers made it easier to detect GFP signal (Table 7).  
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GFP expression was detectable 24 h post stop of Lipofectamine 2000 reaction and 
increased within the next 24 h. After 48 h, expression reached a maximum and after 
approximately 72 h, expression started decreasing (Table 7). For all further luciferase 
experiments 1-1,5x105 cells/24 well plate were chosen as standard cell number and 48 h 
post transfection-stop was chosen as point of detection. 
Cell number Cell density 
after 24 h 
Transfection 
efficiency (24 h) 
Cell density 
after 48 h 
Transfection 
efficiency (48 h) 
1x105 30-40% +++ 60-70% ++++ 
5x105 >60% +++ >95% ++ 
1x106 >80% + >95% ++ 
5x106 >95% + >95% + 
 
Table 7 pGM3-EGFP-Vimentin Lipofectamine 2000 Transfection of CVPC Clone A5. Lipofectamine 2000 to 
DNA Ratio used was 4:1. Transfection efficiency increased overtime and had a maximum around 48 h post 
transfection and slowly decreased thereafter. High cell density strongly influenced transfection efficiency. 
Transfection efficiency was determined by estimating the ratio of GFP positive cells to GFP negative cells. 
4.4.1.2 DNA to Lipofectamine 2000 ratio 
Once a suitable cell number was established we had to choose an optimal DNA to 
Lipofectamine 2000 ratio. DNA (µg) to Lipofectamine 2000 (µl) was suggested to be 
chosen between 1:2 and 1:3, the minimum being 1:0.5 and the maximum being 1:5. We 
therefore chose 1:3, 1:4, and 1:5 as our test concentrations.  
Figure 43 shows fluorescence and phase contrast images of clone A5p14 transfected 
with pGM3-EGFP-Vimentin. No difference in transfection efficiency between varying 
Lipofectamine 2000 concentrations could be detected after 28h and 52h. We therefore 
chose to lower DNA to Lipofectamine 2000 ratio even further. We next tried ratios of 
1:0.5, 1:1, 1:2, and 1:3. Within the latter three no significant variance of transfection 
efficiency could be detected, only ratio of 1:0.5 yielded less GFP positive cells (data not 
shown). A DNA to Lipofectamine 2000 ratio of 1:1 was set as standard for further 
transfections. 
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Figure 43 pGM3-EGFP-Vimentin transfection. Phase contrast images (A), GFP fluorescence (B) after 52h. 
1.5x105 cells were seeded. The DNA to Lipofectamine 2000 ratio is indicated at the bottom. Transfection efficiency 
did not increase when the ratio was increased but stayed stable (bar=50µm). 
4.4.1.3 Medium conditions 
First we performed transfections with 1 ml medium per 24 well. Since less medium 
means a higher chance of reagent-cell interaction, the medium volume was lowered step 
wise to eventually 500 µl per well. Lipofectamine 2000 can be toxic for cells and 
reaction should not continue over night. Medium change was suggested to take place 
between 4 h and 6 h post transfection. We did not detect a significant difference 
between 3 h and 6 h of incubation and therefore 3 h were chosen as standard protocol 
(data not shown).  
In summary, standard protocol was chosen to contain a DNA to Lipofectamine 2000 
ratio of 1:1, transfection time was set to 3 h in 500 µl medium, and detection was 
carried out 48 h post transfection stop. 
4.4.2 Monitoring Nkx2.5 expression 
4.4.2.1 Dilution 
We used the sea pansy (Renilla reniformis) luciferase to determine transfection 
efficiency. Renilla values were often too high to be within the linear detection interval 
and therefore samples had to be diluted. In order to test whether dilution of samples 
alters measured values we performed a dilution assay. Two wells were transfected with 
NKE24 and Renilla according to standard protocol. NKE24 carried a luciferase reporter 
gene under the Nkx2.5 promoter region. Samples were diluted 1:7.5, 1:22.5, and 1:45. 
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Values are mean of the duplicates. The purple graph shows mean value and standard 
deviation of all six measurements (Figure 44).  
Firefly to renilla ratio is slightly influenced by dilution protocol but standard deviation 
between all 6 measurements was very low (σ=0.004). Therefore, we set a dilution of 
1:36 as standard. 
 
Figure 44 NKE Expression. CVPCs A5p22 were transfected with the NKE24 plasmid. NKE24 to renilla ratio was 
chosen to be 1:100. Lysats were diluted in Lysis Buffer as indicated (x=0.08±0.004). 
4.4.2.2 Influence of GFP expression on Luciferase assays 
From transfection experiments with other cell lines we had reason to believe that 
plasmids encoding a green fluorescence protein (GFP) somehow interfered with renilla 
and firefly detection. We therefore wanted to test whether these assumptions held true 
in CVPCs. As seen in Table 8 GFP excitation spectra are rather close to firefly and 
renilla emission spectra. Therefore, we wanted to ensure that GFP does not interfere 
with the detection method. 
To test our theory we used the pmaxGFP plasmid, which encodes GFP under a CMV 
(Cytomegalovirus) promoter. Cells were transfected with pmaxGFP, NKE24, and pUC, 
respectively. 
 emission excitation 
Monster GFP (Promega) 515nm 480-505nm 
pEGFP 507nm 488nm 
firefly 560nm  
renilla 475nm  
Table 8 Emission scale. Excitation spectra of GFP are close to emission levels of firefly and renilla. We were 
concerned that there might be an interference with renilla and firefly emission. Monster GFP is derived from 
Montastrea cavernosa (Great Star Coral). 
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As seen in Table 9, renilla values were strongly reduced when GFP plasmid was co-
transfected, which went hand in hand with previous results from other cell lines. This 
concerned us since renilla luciferase activity was our indicator of transfection 
efficiency. Firefly values were also reduced when GFP was co-transfected. Since the 
ratio of firefly to renilla between pmaxGFP and pUC transfection was not strongly 
influenced (σ=0.0025) we decided that we could continue transfection experiments.  
 
NKE Firefly (F) Renilla (R) FF/R Mean σ 
+pUC 3990 167220 0,0239 
0,0233 0,0018  4440 180040 0,0247 
 5090 238890 0,0213 
+pmaxGFP 2150 117770 0,0183 
0,0197 0,0015  2000 102340 0,0195 
 2210 104050 0,0212 
Table 9 Influence of GFP on luciferase detection. Renilla values indicate transfection efficiency and are used to 
standardize measurements. Transfection efficiency was much lower when GFP plasmid was co-transfected. Ratio of 
firefly to renilla stayed approximately the same.  
4.4.2.3 Nkx2.5 expression in CVPCs 
We transfected CVPCs with the NKE24 plasmid to monitor the Nkx2.5 promoter 
activation by measuring the luciferase reporter gene levels. NKE24 encodes the 
luciferase gene under the control of the Nkx2.5 promoter region (NKE). Control cells 
were transfected with a pGL3b plasmid encoding a luciferase gene without a promoter 
region (pGL3b). 
Cells were transferred onto gelatin coated plates one day prior to transfection. Figure 
45B shows NKE luciferase values relative to pGL3b luciferase values. The Nkx2.5 
promoter was indeed activated in CVPCs since luciferase activity of NKE transfected 
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cells was more than 30fold higher relative to pGL3b luciferase activity. Next we 
decreased the NKE24 Plasmid-DNA amount to 50% and used the pUC plasmid to 
compensate DNA decrease. This lead to a reduction of luciferase reporter gene activity 
by around 50%. This showed that an addition of a second plasmid to the Lipofectamine 
2000 reaction had no negative influence on the reporter gene activity. In Figure 45A the 
firefly values of the same experiment are shown relative to the renilla values.  
 
Figure 45 Luciferase gene expression. A5p28 was seeded at 105cells/24 well. The plasmid DNA to renilla ratio was 
100:1, the total DNA amount was 1000ng DNA (DNA ratio: pGL3b 100%, NKE 100%, pGL3b+pUC 50%+50%, 
NKE+pUC 50%+50%). Luciferase was predominantly produced in cell lines transfected with the NKE24 plasmid, 
cell lines lacking this plasmid showed weak expression (A). The firefly/renilla ratio relative to pGL3b levels is shown 
in (B). Transfection of half the NKE plasmid amount reduced firefly/renilla values to approximately one half of the 
original values.  
4.4.2.4 Influence of BMP2 and SPARC on Nkx2.5 expression 
From preliminary experiments we knew that SPARC had a positive influence on 
cardiomyogenesis in CVPCs (H.Auner, unpublished results). Earlier we showed that 
BMP2 positively influences cardiomyogenesis in CBs. We wanted to investigate if we 
can observe a change in Nkx2.5 promoter activation rate after addition of BMP2 or 
SPARC.  
Standard transfection protocol was used and BMP2 (100 ng/ml) and SPARC (1 µg/ml) 
were added right after Lipofectamine 2000 reaction was stopped. Triplicates were made. 
As seen in Figure 46 no significant differences in luciferase reporter expression were 
detected within the tested timeframe. This does not exclude that SPARC and BMP2 can 
influence Nkx2.5 expression but rather shows what within 48 h no significant change in 
expression rate can be detected.  
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Figure 46 Nkx2.5 activation by BMP2 and SPARC. A5p27 (A) and A5p14 (B) were transfected with the NKE24 
plasmid and the renilla plasmid at a ratio of 100:1. BMP2 and SPARC have no influence on Nkx2.5 promoter 
activation 48h post transfection. Luciferase values are shown in appendix (Table 13). 
4.4.2.5 Influence of Desmin on Nkx2.5 expression 
We previously found that Desmin can bind to the Nkx2.5 promoter region in mESCs 
AB2.2 and DC6 (Desmin over-expressing cells) (C.Fuchs, S.Gawlas, unpublished data). 
We wanted to see if in CVPCs over-expression or knock-down of Desmin influences 
Nkx2.5 expression. We therefore transfected CVPC clone A5 with Desmin encoding 
vector pBK-RSV-Desmin; Desmin siRNA expressing vector knockdown-4 (kd-4); 
random, non-coding siRNA expressing vector knockdown-control (kd-ct); and NKE24 
as a reporter vector, respectively. 
We detected an activation of the Nkx2.5 promoter region in all NKE24 transfected 
clones, luciferase signal was minimal when transfected with pGL3b alone. 
Overexpression of Desmin by the pBK-RSV-Desmin vector did not result in the 
expected activation of the Nkx2.5 promoter region and the consequential expression of 
the luciferase reporter gene (Figure 47). Co-transfection of NKE24 with any other 
plasmid than pUC resulted in a strong downregulation of luciferase reporter gene 
activity. Interestingly, transfection efficiency relative to pGL3b varied strongly between 
the experiments but within the individual experiments it remained proportional (Figure 
47). 
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Figure 47 Luciferase Assay of CVPC clone A5. Cells were transfected at a plasmid to renilla ratio of 100:1. DNA 
level was kept constant at 1000ng, 330ng of each plasmid was used (Renilla 10ng), vector pUC was used to 
compensate DNA amount. (A), (B), and (C) show firefly/renilla values relative to pGL3b values of three individual 
experiments. Although transfection protocol was not altered efficiency varied strongly. Average firefly to renilla ratio 
is about 4 times higher in (A) than in (B). Co-transfection of a second plasmid together with the NKE24 plasmid led 
to a strong downregulation of luciferase reporter gene activity. Luciferase values are shown in appendix (Table 14, 
Table 15, Table 16). 
As seen in Table 10 viability of cells was influenced depending on transfected plasmids. 
Survival of cells containing a Desmin over-expressing or a Desmin knock-down vector 
was decreased. NKE and kd-ct did not influence viability of cells.  
transfected plasmids viable cells per transfected well after 24h 
NKE +++ +++ +++ 
NKE+Desmin + ++ ++ 
NKE+Desmin+kd-4 ++ ++ + 
NKE+Desmin+kd-ct ++ ++ ++ 
NKE+kd-4 + ++ ++ 
NKE+kd-ct +++ +++ +++ 
Table 10 Viability of transfected cells. 100 000 A5p11 were seeded. Over expression and knockdown of Desmin 
influenced viability of cells within 24h. NKE and kd-ct plasmids did not decrease viability. 
In order to test whether the pBK-RSV-Desmin plasmid was functional we isolated 
protein lysats and performed Western Blot analysis with α-Desmin antibodies. Lane 2 
and 4 show an upregulation of Desmin protein level proofing that transfection of the 
pBK-RSV-Desmin plasmid resulted in an overexpression of Desmin (Figure 48). Signal 
is reduced in lane 2 due to lower protein loading amount compared to other lanes (see 
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GSK3 expression rate), therefore Desmin levels are expected to be even higher than 
shown in lane 2. Lane 3 shows downregulation of Desmin protein level in presence of 
vector kd-4, proofing that vector kd-4 was indeed functional. According to lane 6, 
knockdown control (kd-ct) had no influence on internal Desmin protein levels, while 
Figure 47 shows a reduction of luciferase reporter gene activity compared to 
transfection of NKE by itself.  
 
Figure 48 Western Blot analysis of Desmin protein expression. CVPCs A5p11 were transfected with indicated 
plasmids, pUC was used to balance total DNA amount. GSK3 and GAPDH were used to determine loaded protein 
amount per lane. Desmin is upregulated in lane 2 and 4. Western Blots of two individual experiments are shown in 
(A) and (B). 
4.5 SPARC signaling 
We previously showed a positive influence of SPARC on cardiomyogenesis (H.Auner, 
unpublished data). Therefore, we wanted to investigate the SPARC signaling pathway.  
4.5.1 Proof of method 
Leukemia Inhibitory Factor (LIF) signals via the Stat3 and MAPK pathway. Since an 
effect of LIF on Stat phosphorylation was reported to take place within 30 min protein 
lysats were prepared at time point zero, 4 min, 10 min, 30 min and 60 min (Rajasingh et 
al., 2007). Medium was changed at time point zero and M-LIF (100ng/ml) and BMP2 (2 
µg/ml) were added to samples termed 4 min, 10 min, 30 min and 60 min. Proteins of 
sample 0 min were isolated without a medium change. 
Upon M-LIF addition, phosphorylation of Stat3 was induced after 4 min relative to 
overall Stat3 level. Phosphorylation led to an activation of the Stat3 pathway. pErk 
levels were not increased under these conditions in two independent experiments 
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(Figure 49). Therefore MAPK signaling was not induced within 1 h after M-LIF 
addition. 
 
Figure 49 Western Blot M-LIF Induction. Cells were treated with 100ng/ml M-LIF at timepoint zero. Proteins 
were isolated at 0, 4, 10, 30, and 60 minutes after induction. Western Blots with Stat3, pStat3 and pERK1/2 
antibodies were made. (A) shows upregulation of pStat3 10 min after M-LIF induction relative to total amount of 
Stat3. pErk1/2 levels are not influenced under these conditions. (B) shows activation of Stat3 at 4 min and 10 min 
compared to pErk1/2 levels. 
To further proof our method we induced cells with BMP2 and tested for activation of 
Smad1/5/8 by phosphorylation. An increase of pSmad1/5/8 was detected after 10 
minutes and further increased after 30 min and 1 h (Figure 50). No increase of 
pSmad1/5/8 was seen in controls (not shown). BMP2 had no influence on 
phosphorylation of Stat3.  
 
Figure 50 Western Blot BMP2 Induction. Cells were treated with 2 µg/ml BMP2 at timepoint 0 min. Proteins were 
isolated at 0, 4, 10, 30, and 60 minutes after induction. Western Blots with pStat3, pSmad1/5/8, and GAPDH 
antibodies were made. Addition of BMP2 did not influence phosphorylation of Stat3 but lead to an increase of 
phosphorylation of Smad1/5/8. 
Since we could both induce phosphorylation of Smad1/5/8 by BMP2 addition as well as 
phosphorylation of Stat3 after LIF addition we concluded that out method was 
functional.  
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4.5.2 SPARC signaling 
SPARC has been reported to bind to β-Integrin 1, which is linked to ILK1. ILK1 
influences phosphorylation of GSK3 and therefore the Wnt Pathway (Weaver et al., 
2008).  
Phosphorylation of GSK3 was shown to take place within 5-30 min after signal 
induction (Markou et al., 2008). If SPARC signaled trough GSK3 inactivation - thereby 
influencing the Wnt Pathway - we should have seen an increase in GSK3 
phosphorylation.  
We chose timepoints 0, 4, 10, 30, and 60 minutes after SPARC addition for protein 
isolation. At timepoint 0 medium was changed to eliminate SPARC secreted by CVPCs 
Recombinant SPARC was added to growth medium. Medium of sample 0 min was not 
changed, since isolation took place immediately.  
At first we detected a noticeable decrease of Glycogen Synthase Kinase 3 α+β (GSK3) 
phosphorylation of Serine 9 and Serine 21 after 4 min and 10 min, meaning an 
activation of GSK3. GSK3 phosphorylation levels were back to initial levels 30 min 
post SPARC induction (T. Gottschamel, unpublished results). 4min after SPARC 
induction we could show a decrease in phosphorylation of Akt (also referred to PKB or 
Rac), arguing that Akt was rendered inactivate (Figure 51). One of the essential 
functions of Akt is the negative regulation of GSK3 activity by phosphorylation. 
Inactivation of Akt leads to an activation of GKS3 which goes hand in hand with the 
reported activation of GSK3. pStat3 levels were not influenced by addition of SPARC 
to growth medium (Figure 51). 
 
Figure 51 SPARC Signaling. Proteins were isolated for sample 0 min and growth medium of the remaining wells 
was changed, point of medium change was termed timepoint 0. SPARC (0.3µg/ml) was added at timepoint 0 min. A 
strong decrease in Akt phosphorylation could be detected, level of Stat3 phosphorylation was not influenced.  
Since we wanted to test through which signaling pathway SPARC can regulate gene 
transcription we tested the influence of MAPK pathway inhibitor PD98059 and GSK3 
inhibitor Chir99021 in combination with SPARC.  
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PD98059 was added 45min before reaction start therefore medium change took place 
45min before timepoint 0. SPARC was added at timepoint 0. Influence of SPARC on 
pAkt could no longer be detected and pGSK3 levels were increased (Figure 52A). This 
was surprising since block of MAPKK1 activation should not interfere with the 
activation of Akt and also not with the deactivation of GSK3. Controls showed no 
elevation in pGSK3 level induced by PD98059 after 45min of treatment (Figure 52B). 
Unfortunately, we showed that the medium change at timepoint 0 min severely 
interfered with phosphorylation of GSK3 and Akt (Figure 53). Since protein isolation 
protocol used for experiments proved to be unsuitable no further Western Blot data is 
shown. 
 
Figure 52 SPARC and inhibitor of MAPK induction. (A) MAPK pathway inhibitor PD98059 (10-5M) was added 
to wells 45 min prior to SPARC (0.3µg/ml) (induction at timepoint zero. Timeperiod of SPARC induction is 
indicated. GSK3 was inactivated after 4 min, pAkt and pStat3 levels were not influenced. (B) Growth medium was 
changed 45 min prior to protein isolation. PD98059 (=P) was added at a concentration of 10-5M upon medium 
change. After 45 min of PD98059 treatment no influence on pGSK3 or Stat3 level could be observed. 
4.5.2.1 Change of growth medium influences GSK3 phosphorylation 
We proved that protein isolation protocol worked for the Stat3 and the Smad pathway. 
But protocol seemed to influence phosphorylation of GSK3 and Akt.  
We tested whether feeding protocol influenced pGSK3 and pAkt levels. Medium was 
changed 2 h prior to protein isolation for control 1 and 2. Proteins of control 1 and 
timepoint 0 min of control 2 were isolated without a second medium change. Growth 
medium of remaing wells of control 2 were changed at timepoint 0.  
Figure 53 reveals that medium change at timepoint zero was responsible for 
downregulation of pGSK3 after 4 min while pStat3 and pErk1/2 levels were not 
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influenced. Since all other Western Blot experiments were performed under these 
conditions we could not draw any conclusions from them and no further Western Blot 
data is shown. 
Since CVPCs express high levels of SPARC within 2 h and therefore we could not 
adapt our protein isolation protocol. According to Figure 53 the medium change would 
have to take place at least 30 min prior to SPARC induction in order to avoid an 
influence on pGSK and pAkt levels. 
 
Figure 53 Change of growth medium influences pGSK3 level. Growth medium of samples was changed at time 
point zero as indicated. This medium change resulted in a deactivation of GSK3 by phosphorylation. Erk2 and Stat3 
phosphorylation levels were not influenced. 
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5 Discussion 
Recently, cardiac stem cell-like cells (CSCs) have been discovered in the adult heart. To 
better understand the self-renewal capacity of the murine heart, it is necessary to 
establish a model system in which molecular and cellular mechanisms of the progenitor 
cell reactivation and the underlying cytokine influences can be studied. Here we report 
the isolation of a stable Cardiovascular Progenitor Cell (CVPC) line from the murine 
heart which exclusively differentiates to cardiomyocytes, smooth muscle cells, and 
endothelial cells. The potential of these cells is limited and we reason that these cells 
might therefore provide new opportunities for the regeneration of injured heart tissue in 
the future. Restricted potency of these cells also implicates lower risks than ESC 
therapy. We propose that the CB system is a valid system for the study of CVPC 
differentiation. It allows better investigation of the pathways thriving and inhibiting 
differentiation of these cells. Furthermore the most important differences and 
similarities between CVPCs and the most commonly studied mESCs were determined. 
We show that LIF is sufficient to maintain CVPC self-renewal and negatively effects 
differentiation. We demonstrate that inhibition of LIF signaling is essential to induce 
cardiomyogenesis and LIF is dominant over the positive influence of BMP2 on 
cardiomyogenesis. BMP and Stat3 signaling play a time dependent role during 
cardiomyogenesis.  
5.1 Isolation of a stable cardiovascular progenitor cell line 
The heart was thought to be one of the least regenerative organs in the human body 
(Laflamme and Murry, 2005). Cardiomyocytes were believed to terminally differentiate 
and withdraw from the cell cycle after birth. Therefore myocardial injury would result 
in permanent myocardial loss and to cardiac dysfunction (Oyama et al., 2007; Towbin 
and Bowles, 2002). Recently, CSCs have been isolated by various groups suggesting 
that the heart maintains self-renewal capacity after birth (Beltrami et al., 2003; Oh et al., 
2003; Oyama et al., 2007; Pfister et al., 2005).  
Here we report the isolation of the first stable cardiovascular progenitor cell (CVPC) 
line from neonatal mice (Weber, 2006; Wiedner, 2008). CVPC isolation protocol 
included a co-culture step with mESC line AB2.2. Here we show that CVPCs are 
euploid and not aneuploid fusion products of mESCs and somatic cells. We have 
successfully cultured CVPCs up to passage 68 without a detectable loss in multipotency 
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or self-renewal capacity. Thereby we provide further proof that the murine heart 
maintains a regenerative capacity after birth. 
5.2 CVPCs simultaneously express stemness markers and cardiac linage 
markers  
CVPCs express at least three stemness factors, namely Sox2, Nanog, and Oct3/4 at a 
level comparable to murine ESCs. Expression of these three transcription factors give 
CVPCs the potential to remain in the undifferentiated stem cell state. CVPCs express 
cardiac markers such as Nkx2.5 and α-MHC simultaneously with stemness factors. 
Upon LIF deprivation and consequential differentiation, the expression of the stemness 
factors is downregulated and lost eventually, leading to terminal loss of multipotency. 
Oh et al. (2003) reported the isolation of cardiac progenitors from the adult murine 
heart. These cells did not express cardiac markers Nkx2.5 and α-MHC, but did express 
cardiac markers such as MEF2c and GATA4 on mRNA level in the undifferentiated 
state. Oyama et al. (2007) reported no expression of cardiac markers in the 
undifferentiated state of their isolated CSCs. In contrast, CVPCs expressed MEF2c, 
GATA4, as well as Nkx2.5 and α-MHC on mRNA level in the undifferentiated state. 
Therefore we reason that our CVPC clones are further downstream of these more 
primitive progenitor cells and possibly further committed to the cardiac lineage. 
Expression of stemness genes proves that CVPCs have stem cell character and can 
remain in the undifferentiated state. Co-expression of cardiac lineage markers shows 
that CVPCs are not pluripotent as mESCs but that differentiation potential is limited to 
cell types of the heart. The difference in expression pattern of CVPCs distinguishes 
them from CSCs isolated by other groups. The fact that CVPCs appear to be a so far 
unique cell line might also explain why we were able to culture CVPCs up to passage 
68 while others could not. 
5.3 CVPCs differentiate to cardiomyocytes in the absence of inductive 
signals 
So far differentiation of CSCs to cardiomyocytes was reported to be induced in response 
to 5’-azacytidine (Oh et al., 2003), in response to oxytocin and trichostatin (Oyama et 
al., 2007), or by co-culture with adult cardiomyocytes (Pfister et al., 2005). 
Differentiation of mESCs AB2.2 in the monolayer system never yielded beating 
cardiomyocytes. Here we show differentiation of CVPCs to cardiomyocytes, smooth 
muscle cells, and endothelial cells without the addition of differentiation inducing 
substances or co-culture with adult cardiomyocytes. In our hands, deprivation of LIF 
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was sufficient to induce CVPC differentiation in regular growth medium. 
Differentiation potential of CVPCs remained limited to smooth muscle, cardiomyocyte, 
and endothelium formation and could not be increased by addition of LIF, BMP2, 
GSK3 inhibitors, or MAPK inhibitors. The fact, that differentiation to non-cardiac 
lineage cells could not be forced further supports that future use of CVPCs for treatment 
of cardiac injuries limits risk compared to mESCs since CVPCs are strongly committed 
to the cardiac lineage. Taken together this means that CVPCs are already pre-destined 
to differentiate into cells of the cardiac lineage and that this differentiation process is 
initiated once self-renewal is no longer aided. 
5.4 The Cardiac Body model system 
CVPCs started differentiating in the absence of LIF. We wanted to establish a more 
reproducible system to study CVPC differentiation than the monolayer system. 
Embryoid Bodies (EBs) are used as an in vitro model system to investigate early steps 
of embryogenesis (Doetschman et al., 1985; Martin and Evans, 1975). We reasoned that 
3D-aggregation of CVPCs in the absence of contact to artificial surfaces might mimic in 
vivo heart formation better than cell surface attachment in the monolayer culture 
system. We adapted our standard EB protocol for the formation and named CVPC-
derived structures Cardiac Bodies (CBs) (Hofner et al., 2007; Weitzer et al., 1995). In 
comparison to EBs, CBs only gave rise to endothelial cells, smooth muscle cells, and 
cardiomyocytes. First beating cardiomyocytes were observed on day 11. This is 6 days 
earlier than in the monolayer system. The onset and degree of cardiomyogenesis was 
reproducible in the CB system, while these factors varied between experiments in the 
monolayer system. The CB system was not as dependent on starting cell number and 
feeding protocol as the monolayer system. Taken together, we reason that the CB 
system is a reliable system to study early stages of cardiomyogenesis and provides a 
microenvironment that is beneficial for cardiomyogenesis compared to the monolayer 
system. The number of cardiomyocytes per overall cell number was increased, the onset 
of cardiomyogenesis was enhanced and the timeframe in which first cardiomyocytes 
were observed was narrowed. Therefore, the CB system allowed us to investigate the 
influence of external factors on cardiomyogenesis in a more controllable approach than 
the monolayer system. 
The formation of smooth muscle cells depended on unknown factors and was only 
observed sporadically. Within one culture plate, containing between 10 and 90 CBs, 
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only few developed contracting smooth muscle cells although CBs were exposed to the 
same growth medium. Therefore, smooth muscle formation appeared dependent on 
locally restricted secreted factors or entirely independent of secreted factors. So far we 
do not understand the mechanisms driving smooth muscle development but we could 
show that neither BMP2 nor M-LIF had a beneficial effect on smooth muscle formation. 
5.5 CVPCs differ from mESC in cell morphology and differentiation 
potential 
Morphology of CVPCS differs from mESCs while doubling time of CVPCs is 
comparable to doubling time of mESCs (Lauss et al., 2005). Furthermore CVPCs have a 
limited differentiation potential compared to pluripotent mESCs. The risk of 
differentiation to unwanted cell types upon injection into the murine heart would 
therefore be lower than the risk of mESC injection. If we understand the mechanisms 
initiating differentiation to cardiomyocytes, a reactivation of dormant progenitor cells 
could be induced after myocardial infarction in the future.  
5.6 CVPCs express SPARC 
Recombinant SPARC was shown to increase cardiomyogenesis in EBs, while addition 
of anti-SPARC antibodies attenuated the effect. mESCs AB2.2 express SPARC on 
mRNA level but do not secrete SPARC protein (Stary et al., 2005). Here we report a 
cell autonomous expression of SPARC by CVPCs. We could demonstrate both 
intracellular and extracellular localization of SPARC in CVPCs. This further 
distinguishes CVPCs from mESC, which do not secret SPARC. Autocrine SPARC 
signaling might therefore play a role in cardiomyogenesis of CVPCs. Due to the high 
levels of cell autonomous SPARC secretion we were not able to determine the pathways 
through which SPARC signals in CVPCs. However, we could show an upregulation of 
ILK on mRNA expression level during CB development. SPARC was shown to 
influence Wnt signaling through ILK (Nie and Sage, 2009). It remains to be determined 
if ILK upregulation in CVPCs is linked to SPARC signaling.  
5.7 LIF is sufficient for CVPC self-renewal 
The isolation procedure of CVPCs included culture on SNL76/7 LIF-producing feeder 
cells. LIF is known to maintain mESC in an undifferentiated state (Niwa et al., 1998; 
Raz et al., 1999; Williams et al., 1988). Zandstra et al. (2000) showed that addition of 
LIF to mESCs potentiates the choice towards self-renewal and away from 
differentiation in cells undergoing cell division. Here we show that recombinant LIF or 
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feeder cell-secreted LIF are sufficient to maintain self-renewal and inhibit 
differentiation of CVPCs. Furthermore, we demonstrate a positive effect of M-LIF on 
growth rate of CVPC. However, Zandstra et al. (2000) reported no immediate impact of 
LIF on proliferation or survival of mESCs. Raz et al. (1999) showed a correlation 
between LIF concentration and proliferation for one out of two tested mESC lines. 
Together, this means that LIF-associated cell proliferation varies within mESCs. Here 
we show that CVPC cell proliferation is indeed LIF-associated and that a LIF 
deprivation results in a decrease of growth rate. 
In mESCs an autocrine LIF production or an autocrine non-LIF gp130 ligand 
production was suggested to temporarily maintain mESCs in self-renewal after LIF 
deprivation. This effect was shown to be cell number dependent (Davey and Zandstra, 
2006; Zandstra et al., 2000). In case this holds true for CVPCs, it would explain why 
successful differentiation in the monolayer system was highly cell number dependent. 
We observed that high amounts of cardiomyocytes only developed when the seeded cell 
number was low. When the cell number was chosen too high, cardiomyogenesis did not 
take place and cells appeared undifferentiated. Whether an autocrine production of LIF 
or a non-LIF gp130 ligand takes place in CVPCs will be tested in the future. Addition of 
anti-LIF antibodies, anti-LIFR-antibodies, or anti-gp130 antibodies, respectively, should 
show if CVPCs are able to form beating cardiomyocytes when seeded at higher cell 
numbers. If so, CVPC differentiation is inhibited by an autocrine LIF/gp130-lignad 
production at high cell density. The addition of M-LIF antibodies to the CB system 
resulted in an earlier onset of cardiomyogenesis as well as an increased number of 
cardiomyocytes per CB. This strongly indicates that an autocrine LIF production does 
indeed take place in CVPCs. 
5.8 LIF negatively affects cardiomyogenesis in the CB system 
Here we showed a negative effect of LIF on CB development. CBs treated with LIF 
during day 0-4.7 showed severely hampered CB development. CB size was decreased, 
cell spreading was impeded, and cardiomyocyte formation was delayed by 6 days. In 
contrast, addition of anti-LIF antibodies during that time period resulted in an increase 
of cardiomyocytes per CB. Cardiomyocyte formation in 100% of CBs was reached 4 
days earlier in anti-LIF treated CBs than in untreated CBs. Although addition of LIF at 
all time points of CB development resulted in drastically decreased cardiomyogenesis 
per CB, its influence was the most critical during the first 5 days. We showed that LIF is 
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a strong inducer of self-renewal and inhibits differentiation of CVPCs. Therefore, 
inhibition of LIF signaling appears to be important during cardiomyogenesis in a time 
dependent manner. These results are in line with the findings that LIF maintains self-
renewal and suppresses differentiation in mESCs (Niwa et al., 1998; Raz et al., 1999; 
Williams et al., 1988). 
In contrast, we saw a positive effect of LIF on cardiomyogenesis in the monolayer 
system. It is notable, that in the monolayer system we treated CVPCs with LIF for a 
time period prior to onset of differentiation while in the CB system we treated CVPCs 
during differentiation. We reason that the increase in cardiomyogenesis of M-LIF 
treated cells compared to cells grown on feeder layers is mainly due to the absence of 
other factors secreted by feeder cells that might negatively affect differentiation or aid 
self-renewal. This might also explain the immediate onset of cardiomyogenic program 
upon LIF deprivation. In conclusion we do not think the monolayer system represents a 
good model for the investigation of the events underlying cardiomyogenesis. Slight 
changes in the feeding protocol, minimal cell number changes, and other unknown 
factors had significant influences on cardiomyogenesis, problems that were not 
observed in the CB model. The most significant finding from the monolayer system was 
that CVPCs can form cardiomyocytes, smooth muscle cells, and endothelial cells in the 
absence of LIF without the need of inductive signals.  
5.9 BMP2 enhances cardiomyogenesis in the CB system 
mESCs treated with BMP2 for 24 h prior to EB formation resulted in a more than 
twofold increase of contracting areas and an enhanced myofibrillogenesis by day 9, 
compared to EBs from untreated mESCs (Behfar et al., 2002). Here we report a positive 
influence of BMP2 on cardiomyogenesis in CBs. Addition of BMP2 on day 4.7 or day 7 
resulted in a 1.5fold increase in cardiomyocyte formation per CB. Furthermore, 
cardiomyocyte formation in 100% of BMP2 treated CBs was reached up to 4 days 
earlier than in control. Addition of anti-BMP2/4 antibodies delayed onset of 
cardiomyogenesis by a maximum of 2 days but had only low influence on the number 
of cardiomyocytes per CB. The morphology of BMP2 and anti-BMP2/4 treated CBs 
was indistinguishable from untreated CBs. Taken together, BMP2 has a strong positive 
effect on cardiomyogenesis, which is further supported by the upregulation of 
pSmad1/5/8 signaling during CB development. We showed that pSmad1/5/8 signaling 
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was upregulated in CBs on day 7 and day 13, independent of treatment with BMP2. 
Inhibition of BMP2 does not prohibit cardiomyogenesis but impedes it. 
In comparison, from the monolayer system we learned that BMP2 is insufficient to 
maintain CVPCs in self-renewal. Cell number was constantly declining and cell death 
was frequently observed in the absence of LIF. After 31 days of culture of CVPCs 
under continuous BMP2 treatment in the absence of LIF the potential of CVPCs to form 
beating cardiomyocytes was severely diminished. Survival was severely influenced and 
a lot of these cells most likely lost stem cell character during the 30 days of LIF 
deprivation. The fact that some cells still maintained the potency to form 
cardiomyocytes showed that a low number of CVPCs survived an entire month of LIF 
deprivation. From these results we can conclude that BMP2 is insufficient to maintain 
self-renewal of CVPCs but cannot draw conclusions about the influence of BMP2 on 
cardiomyogenesis. 
When LIF was added in combination with BMP2 the number of formed cardiomyocytes 
correlated with the number of cardiomyocytes formed by CVPCs grown on feeder cells. 
One explanation for this is that BMP2 aids self-renewal and further inhibits 
differentiation in the presence of LIF by inducing the inhibitor of differentiation genes 
but is not sufficient to maintain self-renewal in the absence of LIF.  
5.10 Inhibition of GSK3 does not affect CVPC multipotency 
During EB development Wnt signaling is required for the commitment of mesodermal 
cells into a cardiomyocyte lineage (Naito et al., 2006). Addition of Wnt3a or GSK3-β 
inhibitor BIO between day 0 and 3 resulted in an increase of beating EBs, while in late 
phases of cardiac development Wnt signaling inhibits proliferation and/or maturation of 
committed cardiomyocytes. Here we show that continuous GSK3 inhibition by 
Chir99021 negatively influences cardiomyogenesis in the monolayer system. We 
demonstrated that even after 20 days of LIF deprivation and GSK3 inhibition, a pool of 
multipotent CVPCs survived and could give rise to CBs with normal cardiomyocyte 
development. Whether a time restricted inhibition of GSK3 has beneficial effects on 
cardiomyogenesis cannot be concluded from these results. 
5.11 Transfection of CVPCs using Lipofectamine 2000 
Here we report the establishment of a transfection protocol for CVPCs using 
Lipofectamine 2000. We show that GFP encoding plasmids have a negative effect on 
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Luciferase detection. We could prove an activation of the Nkx2.5 promoter region in 
CVPCs after 72 h of culture on gelatin. Since Nkx2.5 is an early cardiac marker, this 
means that the cardiac program is already initiated at this time point. However, we 
could not show a direct influence of SPARC or BMP2 on Nkx2.5 expression within a 
48 h timeframe. If Nkx2.5 expression is positively regulated by BMP2 or SPARC at 
other time points cannot be deduced from these results. Stary et al. (2005) showed an 
upregulation of Nkx2.5 expression on mRNA level 4 h after SPARC addition in EBs on 
day 7 as well as in primary fetal cardiomyocytes. This discrepancy between these 
results and ours might be explained by the fact that both primary fetal cardiomyocytes 
as well as EBs on day 7 are already much further progressed in the cardiomyocyte 
formation than CVPCs are after 72 h. Therefore, SPARC might enhance 
cardiomyogenesis in a time dependent manner. 
5.12 Desmin overexpression and knockdown negatively effects CVPC 
survival 
Constitutive overexpression of Desmin in mESCs was shown to transiently upregulate 
Nkx2.5 expression in EBs (Hofner et al., 2007). Transfection of CVPCs with Desmin 
encoding plasmid resulted in a significant increase of intracellular Desmin 
concentration but did not result in an upregulation of Nkx2.5 expression. Co-
transfection with a plasmid encoding a Desmin siRNA (kd-4) diminished Desmin 
expression, while a non-coding siRNA expressing plasmid (kd-ct) did not affect Desmin 
levels. Suprisingly, co-transfection of each of these plasmids with the NKE24 plasmid 
led to a downregulation of Nkx2.5 expression. Hofner, et al. (2007) reported a Nkx2.5 
activation by Desmin between day 2 and 4 of EB differentiation. Therefore, the 
timeframe we chose for Nkx2.5 activation by Desmin might not be optimal, especially 
since we worked with the monolayer system in which cardiomyogenesis is delayed 
compared to EB development. We reason that the overexpression of Desmin might 
result in a negative feedback loop when reaching a certain Desmin threshold but we 
could not explain why co-transfection with a non-coding siRNA expressing plasmid 
(kd-ct) had a negative effect on Nkx2.5 expression, although it did not affect 
intracellular Desmin levels and toxicity of this vector was ruled out. Here we show that 
both overexpression and downregulation of Desmin have negative effects on CVPC cell 
survival. Transient transfection of CVPCs did not allow us to measure Luciferase 
activity more than 96 h post transfection. To further investigate influence of Desmin 
overexpression and knockdown in CVPCs stable cell lines need to be generated. 
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5.13 The study of Cardiovascular Progenitor Cells will contribute to the 
better understanding of the postnatal regenerative potential of the 
murine heart 
The mechanisms underlying the differentiation of cardiac precursor cells to mature 
cardiomyocytes are not fully known and are predominantly studied during 
embryogenesis. It remains to be investigated whether the reactivation of stem cells in 
the mature heart underlies the same signal induction cascades as during early heart 
formation. The study of cardiovascular progenitor cells will aid the better understanding 
of the regeneration capacity of the adult heart and might lead to new insights on how to 
initiate differentiation of CVPCs to adult cardiomyocytes in vivo. The greatest benefit 
would be the reactivation of endogenous CVPCs, thereby omitting necessity of 
immunosuppression due to transplantation or injection of donor cells. Here we provide 
further evidence for the existence of CVPCs in the neonatal murine heart. We showed 
that these cells can self-renew in vitro and remain undifferentiated. Their differentiation 
potential is limited to the three cell types of the heart, namely smooth muscle cells, 
endothelial cells, and cardiomyocytes. Further, we introduced the Cardiac Body system, 
a new model to study cardiomyogenesis of CVPCs in vitro. Further investigation of the 
limitations and the potential of murine CVPCs will contribute to a better understanding 
of the regenerative potential of the murine heart. 
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6 Material 
6.1 Chemicals and material for molecular biology 
Chemical Company 
Acetic acid Merck, D 
Acryl amide BioRad, USA 
Agarose, Biozyme LE Biozyme, D 
Aprotinin Sigma, USA 
ß-Mercaptoethanol Loba Feinchemie, A 
Bromphenolblue Sigma, USA 
BSA Roth, D 
Cellular membrane Roth, D 
Coomassie Brilliant Blue R250 Merck, D 
Dabco Sigma, USA 
dNTPs Fermentas, Lithuania 
Dimethylsulfoxid (DMSO) Acros, B 
Dithiothreitol (DTT) Acros, B 
EDTA Acros, B 
EGTA Sigma, USA 
Ethanol Merck, D 
Ethidiumbromide Fluka, CH 
Formaldehyde Merck, D 
Giemsa stain Sigma, USA 
Glycerine Merck, D 
Glycerophsphat Merck, D 
Hydrochloric acid (HCl) Acros, B 
Imidazole Sigma, USA 
Leupeptin Roche, AUT 
Loading Dye Fermentas, Lithuania 
Methanol Merck, D 
Magnesiumchloride Fermentas, Lithuania 
Magnesiumsulfate Fluka, CH 
Milk Powder (Skim Milk) Sucofin 
Mowiol Hoechst, D 
Nalgene Filter Thermo Scientific, USA 
Ni-NTA agarose beads Quiagen, D 
PCR-buffer without MgCl2  Fermentas, USA 
Pepstatin A Roche, AUT 
Ponceau-S Sigma, USA 
Proteinase Inhibitor Roche, AUT 
Pyrophosphate Fluka, CH 
Reverse Transcriptase Buffer Invitrogen, USA 
SDS BioRad, USA 
Sodiumbicarbonate Sigma, USA 
Sodiumchloride Salinen Austria, AUT 
Sodiumfluorid Donauchemie, AUT 
Sodiumhydrogencarbonate LifeTechnologies, USA 
Sodiumhydrogenphosphate Roth, D 
Sodiumhydroxide Merck, D 
Sodium Orthovandate Sigma, AUT 
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Sodium Pyrophosphate Fluka, CH 
Sodiumthiosulfate Merck, D 
Trichloracetic acid Merck, D 
Tris Base LifeTechnologies, USA 
Triton X-100 Sigma, USA 
Tween-20 Sigma, USA 
 
6.2 Chemicals for cell culture 
Chemical Company 
ß-Mercaptoethanol Loba, A 
Ampothericin B Invitrogen, USA 
Chir99021 Axon, NL 
D-Glucose Acros, B 
DMEM powder Gibco, USA 
DMSO (Dimethylsulfoxide) Sigma, USA 
Fetal Bovine Serum (FBS) HyClone, USA 
Fetal Bovine Serum (FBS) Gibco, USA 
Fetal Bovine Serum (FBS) Sigma, USA 
Gelatin Difco, USA 
Glycine Applichem, D 
L-(+)-Glutamin Gibco, USA 
Lipofectamine 2000 Invitrogen, USA 
Mitomycin C Acros, B 
PD 98059 Cayman, USA 
Penicillin G Kaliumsalz Merck, D 
Penicillin / Streptomycin (P/S) Gibco, CH 
Potassium chloride Sigma, USA 
Potassiumhydrogenphosphate Fluka, CH 
Sf-900 SFM medium Gibco, USA 
Sodiumhydrongencarbonate LifeTechnologies, USA 
Streptomycin Sigma, USA 
6.3 Enzymes 
Enzyme Company 
DNAse I, RNase free Fermentas, Lithuania 
Pancreatin Sigma, USA 
Proteinase K Fluka, CH 
RiboLock RNase Inhibitor Fermentas, Lithuania 
RevertAidTM M-MuLV RT Fermentas, Lithuania 
Restriction Enzymes New England Biolabs, USA 
Taq DNA Polymerase Fermentas, Lithuania 
Trypsin LifeTechnologies, USA 
6.4 Proteins 
Protein Company 
Recombinant SPARC Sigma, USA 
M-LIF Purified from insect cells 
BMP2 R&D Systems 
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6.5 Kits 
Kit Company 
EndoFree Plasmid Maxi Kit Qiagen, D 
RNeasy Mini Kit Qiagen, D 
Dual Luciferase Reporter System Promega, USA 
 
6.6 Cell Lines 
6.6.1 SNL76/7-Fibroblasts 
STO Fibroblasts were transfected with a stable neomycin resistance expression vector 
and a LIF expression vector by Allan Bradley (McMahon and Bradley, 1990)  
6.6.2 Bacteria Strain XL1-Blue 
Bacteria strain XL-1 Blue (Stratagene, USA) was used for transformation. 
6.6.3 Embryonic stem cells 
The embryonic stem cell line AB2.2 was isolated by Allan Bradley from 129Sv mice 
(Soriano et al., 1991). The embryonic stem cell line 662 was isolated from a 129Sv/BL6 
N1-2 neoR mouse (Lagger et al., 2002). The embryonic stem cell line 663 was isolated 
from 129Sv/BL6 mice (Lagger et al., 2002). 
6.6.4 Cardiovascular Progenitor Cells 
CVPC cell lines were isolated by Wolfgang Weber from heart tissue of N1-2 neoR mice. 
This mouse line encodes a neomycin-resistance gene in one allele of the HDAC1 locus 
and can therefore survive selection with neomycin or neomycin analogs (e.g. G418). In 
order to increase the isolation success rate these heart tissue derived cells were co-
cultured with murine wild type ESCs. This co-culture was used to supply possible 
cardiovascular progenitor cells with external factors that are usually supplied by the 
stem cell niche. Since niche conditions are unknown, the presence of ESCs and the 
proteins, cytokines, etc. secreted by these, was thought to possibly keep CVPCs in stem 
cell mode. After 10 passages of co-culture (3T3 protocol) on feeder layers a selection 
against hypertrophic cells and towards fast replicating cells had already taken place. 
Addition of the neomycin analog G418 resulted in death of murine wild type stem cells. 
CVPC clones were gained by seeding one cell per plate and expanding this culture 
under treatment of G418. 11 clonal cell lines were derived named A3, A5, B3, B5, C3, 
D3, D5, E3, F3, G3, and H3. 
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6.7 Primers 
Primer name  Primer sequence 
Annealing 
temp 
Cycles 
PCR product 
(bp) 
BAMBI Fwd 5’ – TTCCAAGAGCGAAGCCTCA – 3’ 58°C 30 cDNA 214 
Rev 5’ – CTCATCCTGCAGCCTCTTGT – 3’ Genomic 651 
Brachyury (T) Fwd 5’ – GAACCTCGGATTCACATCGTGAGA – 3’ 60°C 36 cDNA: 159 
Rev 5’ – ATCAAGGAAGGCTTTAGCAAATGGG – 3’ Genomic: 891 
Desmin Fwd 5’ – TGACAACCTGATAGACGA – 3’ 50°C 37 cDNA: 390 
Rev 5’ – TTCTTATTGGCTGCCTGA – 3’ Genomic: 1972 
Desmin Fwd 5’ – TGATGAGGCAGATGAGGGAG – 3’ 50°C 37 cDNA 246 
Rev 5’ – TGAGAGCAGAGAAGGTCTGG – 3’   
GATA4 Fwd 5’ – GCCTGTATGTAATGCCTGCG – 3’ 53°C 31 cDNA: 500 
Rev 5’ – CCGAGCAGGAATTTGAAGAGG – 3’ Genomic: 3364 
GAPDH Fwd 5’ – CGTCTTCACCACCATGGAGA – 3’ 55°C 29 cDNA: 300 
Rev 5’ – CGGCCATCACGCCACAGTTT – 3’ Genomic: 300 
ILK Fwd 5’ – CTCTGCGGTGGTTGAAAT – 3’ 52.5°C 35 cDNA 190 
Rev 5’ – GAAACATGCATAGTGAAGTGG – 3’ Genomic 360 
LIFR  Fwd 5’ – AGGAATGCCACAATCAGAGG – 3’ 57°C 30 cDNA 190 
Rev2  5’ – TCCAAGTGTCTGGTCCCTTT – 3’ Genomic 499 
MEF2c Fwd 5’ – GGCCATGGTACACCGAGTACAACGAGC – 3’ 66°C 34 cDNA: 395 
Rev 5’ – GGGGATCCCTGTGTTACCTGCACTTGG – 3’   
Mesp1 Fwd 5’ – AGAAACAGCATCCCAGGAAA – 3’ 52°C 32 cDNA: 346 
Rev 5‘ – GTGCCTGCTTCATCTTTA – 3’ Genomic: 619 
α-MHC  Fwd 5’ – GGAAGAGTGAGCGGCGCATCAAGG – 3’ 57.7°C 32 cDNA: 302 
Rev 5’ – CTGCTGGAGAGGTTATTCCTCG – 3’   
Nanog  Fwd 5’ – AGGGTCTGCTACTGAGATGCTCTG – 3’ 60°C 28 cDNA: 364 
Rev 5’ – CAACCACTGGTTTTTCTGCCACCG – 3’ Genomic: 4793 
Nkx2.5 Fwd 5’ – CACCCACGCCTTTCTCAGTC – 3’ 57°C 35 cDNA: 513 
Rev 5’ – TGGACGTGAGCTTCAGCA – 3’   
Oct 3/4  Fwd 5’ – CCACCTTCCCCATGGCTGGACA – 3’ 50°C 37 cDNA: 1082 
Rev 5’ – AGGGCTGGTGCCTCAGTTTG – 3’ Genomic: 4475 
OSMR  Fwd 5’ – GGCAAATCACTGAAGGCTCA – 3’ 62°C 30 cDNA: 801 
Rev 5’ – CACACCAGTCCACAACATAG – 3’   
α-
Tropomyosin  
Fwd 5’ – CAAGCGGAGGCTGATAAGAAGG – 3’ 55°C 30 cDNA: 310 
Rev 5’ – TGCCTCTCTCACTCTCATCTGC – 3’   
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6.8 Antibodies 
Antibody Dilution kDa Host Catalog # Company 
Desmin WB 1:300 50-
55 
mouse D1033 Sigma, USA 
Desmin WB 1:200 53 rabbit 8592 Abcam, USA 
Erk1/2 WB 1:300 42 rabbit n.A. Upstate, USA 
GAPDH WB  
1:60 000 
37  MAB374 Millipore, USA 
GSK3 α/β IF 1:50 51, 
47 
mouse 7291 Santa Cruz, 
USA 
Human BMP-2/4    MAB355
2 
R&D Systems, 
USA 
Mouse LIF    AF449 R&D Systems, 
USA 
mouse-FITC IF 1:200  donkey 715-095-
151 
Jackson Labs, 
USA 
p-Akt (Ser473) WB 1:1000 60 rabbit 9271 Cell Signaling, 
USA 
p-Akt (Thr308) WB 1:1000 60 rabbit 9275 Cell Signaling, 
USA 
p-GSK3 α/β (Ser21/9) WB 1:1.000 46, 
51 
 9331 Cell Signaling, 
USA 
p-GSK3 α/β 
(Tyr276/216) 
IF 1:50 51, 
47 
goat 11758 Santa Cruz, 
USA 
p-Smad1 (Ser463/465)/ 
Smad5 (Ser463/465)/ 
Smad8 (Ser426/428) 
WB 1:500 60 rabbit 9511 Cell Signaling, 
USA 
p-Smad2 (ser465/467) WB 1:1000 60 rabbit 3101 Cell Signaling, 
USA 
p-Stat3 WB 1:1000 79, 
86 
rabbit 9131 Cell Signaling, 
USA 
rabbit-FITC IF 1:200  donkey 711-095-
152 
Jackson Labs, 
USA 
Smooth Muscle Actin  IF 1:800  mouse A 2547 Sigma, USA 
SPARC IF 1:50, 
WB 1:200 
43 rabbit 25574 Santa Cruz, 
USA 
Stat3 WB 1:1000 79, 
86 
rabbit 9132 Cell Signaling, 
USA 
Troponin T, Cardiac  
Isoform Ab-1 
IF 1:100-
200 
 mouse MS-295-P Thermo 
Scientific, USA 
WB=Western Blot, IF=Immunofluorescence 
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6.9 Plasmids 
6.9.1 Renilla 
The pRL-TK vector contains a renilla luciferase reporter gene under the control of a T7 
promoter. This plasmid was used as an internal control to measure transfection 
efficiency. 
 
 
 
 
 
 
 
 
 
  
6.9.2 pGL3b 
The pGL3-Basic vector encodes a firefly luciferase gene but lacks a promoter.  
 
 
 
 
 
 
  
  
Promega Renilla Plasmid (#E2241) 
Promega pGL3-Basic Plasmid (#E1751) 
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6.9.3 pUC 
The pUC18 plasmid does not encode for a luciferase reporter gene but is used to 
compensate plasmid DNA amount in transfections with varying plasmid numbers. 
 
 
 
 
 
 
6.9.4 NKE24 
NKE24 is a pGL3b plasmid with the Nkx2.5 promoter inserted in frame with the 
luciferase reporter gene. It was obtained from Dr. Katherine Yutzey (USA). 
 
  
 
 
 
 
 
 
 
 
 
 
6.9.5 Knock down-4  
The kd-4 plasmid encodes for antisense RNA to the murine Desmin mRNA inserted 
into the Promega pGeneClip hMGFP Vector. 
 
   
  
  
 
 
 
 
From Not I 4651  
Nkx2.5Promoter (-3059to +223) 
NKE24 
8,05kb 
Cloned sequence: 
GACCATCGCGGCTAAGAAC
 
Promega pUC18 Plasmid 
pGL3-Basic vector with Nkx2.5 insert 
 
Desmin Knock Down4 Plasmid, Promega (#C8790) 
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6.9.6 Knock down control 
The kd-ct plasmid is identical to the kd-4 plasmid with the exception that it encodes for 
a non-coding RNA. Cloned sequence: GGAATCTCATTCGATGCATAC 
6.9.7 Desmin  
The Desmin plasmid is a PBK-RSV plasmid encoding for the Desmin cDNA under the 
RSV promoter and is used for ectopic Desmin overexpression. 
 
 
 
 
 
 
 
 
6.9.8 pmaxEGFP 
The Amaxa pmaxGFP control plasmid encodes GFP under the control of a 
Cytolmegalovirus promoter (CMV). This plasmid was kindly provided by M.Artaker. 
 
 
 
EcoRI – cDNA DESMIN – BamHI  
Stratagene PBK-RSV vector with a Desmin cDNA insert (#212209) 
Amaxa pmaxGFP plasmid 
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7 Methods 
7.1 Cell culture maintenance 
7.1.1 Washing of glass pipettes  
After use, cotton plug is removed and pipettes are put into vessels containing a mixture 
of water and hypochlorite. After several hours glass pipettes are rinsed with fresh tab 
water for at least four hours. The pipettes are left in MilliQ overnight. Pipettes are dried 
at 80°C for 4 hours, placed in pipette boxes and baked at 180°C for 8 to 10 hours. If 
pipettes come in touch with soap they can no longer be used for tissue culture work with 
ESCs or CVPCs. 
7.1.2 Washing of cell culture glass ware 
Glass ware is filled with hypchlorite and tabwater. After 15-30 minutes bottles are 
rinsed at least five times with tap water and then filled with MilliQ and left overnight. 
Bottles can be emptied and left to dry on the next day. Bottles are autoclaved at 120°C 
at 1.4 bar for 20-30 minutes.  
Magnets and other tissue culture appliances are also washed with hypochlorite and 
MilliQ prior to use and should solely be used for tissue culture and never come in 
contact with soap. 
7.2 Media and solutions 
7.2.1 Solutions 
 
10x PBS (Phosphate buffered saline) 
1.37 M  NaCl 
14.7 mM KCl  
78.1 mM  Na2HPO4x7H2O 
26.8 mM  KH2PO4 
pH 7.2 
Salts are dissolved in 800 ml of MilliQ and titrated to a pH of 7.2 with Na2HPO4x7H2O 
solution. Fill up to 1 l mark with MilliQ and sterile filtrate (Nalgene Filter, Nalgene 
Membrane, 0.22 µm pore width). Solution can be stored at room temperature. 
1x PBS 
Dilute 50 ml of 10x PBS with 450 ml of autoclaved MilliQ in laminar flow.  
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100x GPS (Glutamine-Penicillin-Streptomycin) 
4.25 g  NaCl  
1.5 g  Penicillin  
2.5 g  Streptomycin  
14.6 g  L-(+)-Glutamine  
Dissolve ingredients in 500 ml of MilliQ and sterile filtrate. Aliquot and store at -20°C. 
Prior to use thaw and resuspend till suspension is clear. Store at 4°C.  
100x ß-Mercaptoethanol (10-2M) 
200 ml  1x PBS  
144 µl  ß-Mercaptoethanol 
Add ß-Mercaptoethanol to PBS and sterile filtrate before aliquoting. Store at -20°C for 
longer time periods and at 4°C when in use. 
Trypsin 
3.5 g  NaCl    
0.5 g  D-Glucose   
0.09 g  Na2HPO4x7H2O  
0.185 g  KCl    
0.12 g  KH2PO4   
0.2 g  EDTA    
1.25 g  Trypsin   
1.5 g  Tris Base   
Add ingredients and fill up to 500 ml with MilliQ and bring to a pH of 7.6 with 
concentrated HCl. Sterile filtrate the solution and aliquot in 50 ml falcons and store at  
-20°C. When in use store at 4°C, mix well before use.  
1% gelatin stock solution 
Dissolve 10 g gelatin in 1 l of MilliQ and autoclave before further use. Store at room 
temperature.  
0.1% gelatin solution 
Dilute 50 ml of 1% gelatin stock solution with 450 ml autoclaved MilliQ. Store at room 
temperature. 
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Dulbecco’s Modified Eagle Medium (DMEM) 
Add 4.5 l to a 5 l Erlenmeyer flask and put on top of a magnetic stirrer. Slowly add 
66.9.g of D-MEM followed by 18.5 g of Natriumhydrogencarbonat. Bring to pH 7.4 
with concentrated HCl. Sterile filtrate and store at 4°C. Pipette 3 ml aliquots of each 
bottle into 6 wells and culture at 37°C, 5%CO2. Check daily under the microscope for 
bacterial growth.  
Culture media 
M10Gi medium for SNL76/7 and feeder layers 
10%  Gibco FBS Serum  
1%  GPS 
89%  DMEM 
 
M10Gi medium for ESCs 
10%  Gibco FBS Serum  
1% β-Mercaptoethanol 
1%  GPS 
88%  DMEM 
 
M15Gi medium for ESCs 
15%  Gibco FBS Serum  
1%  β-Mercaptoethanol 
1%  GPS 
83%  DMEM 
 
M15Hy medium 
15%  HyClone FBS Serum  
1%  β-Mercaptoethanol 
1%  GPS 
83%  DMEM 
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M15Si medium 
15% Sigma FBS Serum 
1%  β-Mercaptoethanol 
1%  GPS 
83%  DMEM 
 
Freezing medium 
60%  DMEM 
20%  FBS 
20%  DMSO 
 
Gelatin coating of cell culture plates: 
Cell culture plates must be coated with gelatin prior to use in order to provide a matrix 
that cells can adhere to. Therefore, 0.1% gelatin is applied to all cell culture plates two 
hours prior to use. Gelatin must be removed before further use of culture dishes. Plates 
coated with gelatin are stored at 37°C, 5% CO2. 
7.3 Maintenance of SNL67/7 
7.3.1 Thawing of SNL76/7 
10 cm culture plates must be coated with gelatin prior to thawing. 
SNL76/7 are stored in cryotubes in liquid nitrogen. Cryotubes are carefully removed 
from liquid nitrogen tank and thawed in a 37°C bath until only a thin icicle is left in the 
tube. Cyrotubes are sprayed with 70% EtOH, dried, placed in the laminar flow and 
flamed before and after opening. Content (1 ml-2 ml) is transferred into a 15 ml falcon 
tube and 10 ml M10Gi are added drop by drop while pivoting over a period of at least 5 
minutes. If M10Gi is added too fast cells will undergo an osmotic shock and burst. 15 
ml falcons are centrifuged at 1000 rpm for 7 minutes at room temperature (Heraeus 
Biofuge, swing out buckets). Pellet is resuspended in 1 ml of M10Gi. Another 3 ml of 
M10Gi are added to 15 ml falcons and content is transferred onto a gelatin-coated 10cm 
culture dish. Falcons are washed with 4 ml of fresh M10Gi and solution is added to 
culture dishes. Check plates the next day and change medium if necessary. 
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7.3.2 Cultivation of SNL76/7 
SNL67/7 cells are cultured at 37°C, 5% CO2. Medium must be replaced by fresh M10Gi 
if color indicator switches to orange. Cells must be split when plate is confluent.  
7.3.3 Splitting of SNL76/7 
When confluent, cells must be split onto new gelatin-coated culture dishes. Plates are 
washed with 4 ml 1x PBS. PBS is applied to remove traces of M10Gi which would 
interfere with the function of trypsin. 1 ml of trypsin is added to culture plate and plates 
are placed into incubator (37°C, 5% CO2) for 5 minutes or until cell contacts are 
dissolved. If unsure, cells can be examined under a light microscope. Cells will display 
a round morphology and are not elongated as in their adhesive state. 3 ml of fresh 
M10Gi are added to culture plates to stop trypsin reaction. Cells are resuspended and 
500 µl are transferred onto gelatin-coated culture plates containing 7 ml of fresh M10Gi 
(for 1:8 splitting). 
7.3.4 Freezing of SNL76/7 
When SNL76/7 are confluent, cells can be frozen. Therefore, cells are washed in 4 ml 
PBS. After removal of PBS 0.7 ml trypsin are added to 10cm plate and placed into 
incubator (37°C; 5%) for 10 minutes. Trypsinized cells are resuspended in 2 ml of 
M10Gi and transferred to a 15 ml falcon tube. 2.7 ml of freezing medium are added 
drop by drop to the suspension. This should be done very slowly. The contents is 
divided into two cryotubes and placed in a styrofoam box which is then sealed with tape 
and placed into a –80°C freezer. After two days cryotubes can be moved to a liquid 
nitrogen tank. 
Freezing medium: 
60%  DMEM 
20%  Gibco FBS Serum 
20%  DMSO 
7.3.5 Generating feeder cells 
All culture dishes used must be gelatin-coated in advance. Confluent SNL76/7 plates 
are used to make feeder cells. All but 4 ml of the medium is removed and 80 µl 
Mitomycin C are added to the culture dishes. After a maximum of 4 hours at 37°C, 5% 
CO2 the supernatant is removed and plates are washed twice with 1x PBS. 1 ml of 
trypsin is added to each plate and placed at 37°, 5% CO2 for 5 minutes or until cells are 
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floating around. Cells are resuspended in 5 ml of M10Gi, if more than one plate is 
trypsinized cells can be pooled (maximum of three plates) and solution is transferred 
into a 50 ml falcon. In order to transfer most cells, plates are washed with an additional 
10 ml M10Gi which can be pooled again. The falcon is centrifuged at 1000 rpm for 7 
minutes (Heraeus Biofuge, swing out buckets) and supernatant is discarded. Pellet is 
resuspended in 10 ml of M10Gi. Cell number is measured with CASY cell counter (10 
µm-30 µm). Cells are diluted till viable cell number per ml reaches 3.5x106. For 24 well 
plates pipette 0.5 ml/well, for 6 well plates 2 ml/well, and for 6 cm plates use 4 ml of 
suspension. Feeder cells can be kept at 37°C; 5% CO2 for up to two weeks and have to 
be fed at least once a week with M10Gi.  
7.4 Maintenance of mouse embryonic stem cells 
To keep mouse ESCs undifferentiated they are co-cultured with feeder cells (see above) 
which express leukemia inhibitory factor. 
7.4.1 Thawing of mESCs 
Thawing of ESCs is quite similar to thawing of SNL76/7. Feeder cells must be fed with 
M10Hy at least 2 hours prior to thawing of mESCs. Cryotubes are removed from liquid 
nitrogen tank, thawed in a 37°C water bath until only a small icicle is left and then 
sprayed with 70% EtOH, placed into laminar and flamed. Content is transferred to 15 
ml falcon tubes and 12 ml of M15Hy are added drop by drop, this should be done 
slowly and tubes should be pivoted after each drop. Tubes are centrifuged at 1000 rpm 
for 6 minutes and supernatant is discarded. Cell pellets are resuspended in 1 ml of pre-
fed feeder cell supernatant and then transferred back onto feeder cells. Wash tubes with 
another 500 µl of fresh M15Hy. Cells most likely do not have to be fed within the next 
48 h. 
7.4.2 Cultivation of mESCs 
ESCs are cultivated at 37°C, 5% CO2. Medium must be replaced by fresh M15Hy daily. 
Cells must be split when plate is confluent.  
7.4.3 Splitting of mESCs 
Feeder cells and ESCs must be fed with fresh M15Hy two hours prior to splitting 
(feeders 2 ml, ESC 0.5 ml). ESCs are washed once with 1x PBS. After removal of PBS 
trypsin is applied to plates (200 µl/24 well; 500 µl/6 well; 1 ml/10cm) and plates are 
placed at 37°C, 5% CO2 for fifteen to twenty minutes. In case of 24 wells 1 ml of 
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M15Hy medium (for all other wells at least thrice the amount of trypsin used) from 
previously fed feeder cells is transferred onto ESCs and resuspended well. For splitting 
1:2 600 µl of suspension are transferred back onto feeder cells (1:3, 400 µl).  
7.4.4 Freezing of mESCs 
Cells are fed 2 hours prior to freezing. Cells are washed with PBS and trypsinized  
(200 µl/24 well) and after 15 minutes at 37°C, 5% CO2 800 µl fresh M15Hy are added 
to 24 wells. Cells are resuspended and transferred into 15 ml falcons. 1.8 ml freezing 
medium is added drop by drop (slow!) to falcons, after each drop falcons must be 
shaken slightly to insure homogenous distribution. After addition suspension is divided 
into two cryotubes, these are labeled and placed into to a styrofoam box, which is then 
sealed and placed at -80°C for at least two days before transfer of cryotubes into liquid 
nitrogen tank.  
Freezing medium:  
60%  DMEM 
20%  HyClone FBS Serum 
20%  DMSO 
7.5 Maintenance of CVPCs 
See 7.4 Maintenance of mouse embryonic stem cells (mESCs). 
7.6 Embryoid bodies and Cardiac Bodies 
7.6.1 Generation of EBs/CBs 
mESCs/CVPCs are cultured on feeder cells in 24 wells and must be split at a ratio of 1:2 
one day before EB/CB formation in order for cells to be in log phase. Cells are fed 2 
hours prior to starting point with M15Si and 6 well plates are gelatin-coated. After 2 
hours cells are washed with 1x PBS and 200 µl of trypsin are added to each 24 well. 
Plates are placed in an incubator at 37°C, 5% CO2 until cell bonds are disassociated. 
800 µl of M15Si are added to stop the reaction and suspension is transferred onto 
gelatin-coated 6 well plates containing 2 ml of M15Si in order to separate stem cells 
from feeder cells. Feeder cells adhere faster to the gelatin-coated surface of the 6 well 
plates while ESCs/CVPCs remain nonattached for a longer period of time. After 50 
minutes of incubation at 37°C, 5% CO2 supernatant is transferred into a 15 ml falcon. 
Suspension is filled up to 10 ml total volume and cell number is measured using a 
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CASY counter. Suspension is diluted with M15Si to a cell concentration of 4x104 
cells/ml for ESCs and 4,5x104cells/ml for CVPCs. 2 ml of these dilutions are enough 
for one 10cm dish of hanging drops. Sterilin culture plates are filled with autoclaved 
MilliQ water (a 4 mm high water level is enough). A repeating pipette is set to 20 µl 
dispension (equals 800 cells per drop). Repeating pipette is held at a 90° angle. Drops 
are placed as close as possible without running risk of merging. Do not place drops too 
close to the edge of the bacterial dish lid to avoid contamination. Flip lid over and place 
on top of water filled bottom half. Place carefully at 37°C, 5% CO2; this timepoint is 
referred to as day 0. At day 4.7 the hanging drop cultures have to be transferred onto 
gelatin-coated 10 cm tissue culture plates to allow attachment of the EBs/CBs to the 
culture dishes. Hanging drop cultures are flamed shortly at the edge. 8 ml of M15Si are 
used to rinse EBs/CBs from the lid onto the bottom of a gelatin coated culture plate. 
Place plates at 37°C, 5% CO2 and do not move for the following 48 h. 
7.6.2 Culture of EBs/CBs 
EBs/CBs must be fed every 3 days with M15Si, medium is only partially replaced (day 
7 and 10: 3 ml of old medium +5 ml fresh medium; day 13 to 24: 4 ml old medium +10 
ml fresh medium, day 25 and thereafter: 5 ml old medium +12 ml fresh medium). 
Partial medium replacement ensures that secreted factors remain in medium at low 
concentration. 
Beating of EBs/CBs is observed on a daily basis; both number of beating EBs/CBs and 
intensity of beating areas is quantified. 
7.7 Isolation of Proteins for SDS-PAGE 
Cells are washed with 37°C 1x PBS and icecold, fresh Kinexus Lysis Buffer (e.g.100 
µl/48 well, 150 µl/24 well) is added immediately. Cells are scraped off and transferred 
into an Eppendorf tube and placed on ice. If necessary, wells can be washed with 
additional 50 µl of Kinexus lysis buffer.  
Kinexus lysis buffer 
20 mM  Tris pH7.0 
2 mM  EGTA 
5 mM  EDTA 
30 mM Sodiumfluorid 
40 mM  Glycerophosphate 
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10 mM  Sodium Pyrophosphate 
2 mM  Sodium Orthovandate 
10 µM  Leupeptin 
5 µM  Pepstatin A 
0.5%  Triton X-100 
Proteinase-Inhibitor (1 tablet per 100 ml) 
7.7.1 Bradford protein concentration measurement 
5x Bradford Stock Solution is diluted 1:5 in ddH2O and 200 µl of solution are 
transferred into each 96 well. 4 µl of sample are added to each well, duplicates are 
made. BSA (2.5 µg/µl, 1.25 µg/ml, 0.625 µg/µl, 0.313 µg/µl, 0.156 µg/µl) gradient is 
used for standard curve. 4 µl of standard dilutions are added to 200 µl of 1x Bradford 
solution in duplicates. Protein concentrations are measured at 595 nm on a Labsystems 
Multiscan RC with the Labsystems Multiscan Genesis Software. Values should be 
below 1. Standard curve is calculated, regression should be above 0.996. Protein 
concentrations of samples are calculated according to standard curve.  
5x Bradford stock solution 
100 mg Coomassie  
50 ml absolute MeOH or EtOH 
50 ml 85% H3PO4 
fill up to 200 µl with dd H2O 
store in the dark 
7.8 SDS-PAGE 
5 ml of running gel is poured and coated with isopropanol. Once the gel is hardened 
isopropanol is removed and stacking gel is poured. SDS-PAGE gels are transferred into 
running buffer. 3x sample buffer is added to samples at a ratio of 1:3. Samples and 
marker are boiled at 95°C for 10 min before applying to gel. SDS-PAGE is run between 
100V and 150V till the loading dye has leaked at the bottom end.  
Running gel 12.5% (makes 2 gels)  
5 ml  PAA 
3 ml  1.5M Tris/HCl pH8.8, 0.4% SDS 
4 ml  ddH2O 
120 µl  10% APS 
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10 µl  TEMED 
Stacking gel 5% (makes 2 gels) 
0.5 ml  PAA 
0.75 ml  0.5M Tris/HCl pH6.8, 0.4% SDS 
1.75 ml  ddH2O 
30 µl  10% APS 
2.5 µl  TEMED 
10x Page buffer 
1.92 M Glycin 
250 mM Tris 
1%  SDS 
3x Sample buffer (Laemmli reducing) 
3 ml  Glycerin 
0.9 g  SDS 
3.75 ml  1.5M Tris/HCl pH8.8 0.4%SDS 
1.75 ml ddH2O 
6 mg  Bromphenolblue 
Aliquot and add 150 µl  
7.9 Western Blotting 
4 Whatmann papers are soaked in 1x blotting buffer and are placed into the semi-dry 
Western Blot gear (Trans Blot SD, Biorad). Nitrocellulose membrane (Whatman, 
Protran) soaked in 1x blotting buffer is placed on top. The SDS-PAGE gel is placed on 
top of all this and topped with 4 more Whatmann papers soaked in 1x blotting buffer. 
Device is closed and run at 400 mA for one hour. After successful Western Blotting 
nitrocellulose membrane is transferred into Ponceau S solution for 5 minutes. Ponceau S 
staining visualizes protein-ladder and protein-bands. Bands of protein ladder are marked 
on nitrocellulose membrane with a charcoil pencil before de-staining with ddH2O. 
10x Blotting buffer 
0.48 M  Tris 
0.4 M  Glycin 
pH 9.1 
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Ponceau-S 
100 mg  Ponceau-S 
100 ml  1% glacial acetic acid 
7.9.1 Antibody incubation and visualization 
Nitrocellulose membrane is blocked in 5% Milk in TBS-T for at least one hour at 4°C. 
First antibody is diluted in 5% Milk TBS-T and incubated at 4°C for at least one hour. 
Incubation is followed by three wash steps in TBS-T for 6-10 min each. Second 
antibody linked to horseradish peroxidase or alkaline phosphatase is diluted in 5% Milk 
TBS-T and incubated for at least 1h.  
5% Milk in TBS-T 
5%  Skim Milk Powder  
0.1%  Tween-20 
TBS 
10x TBS 
0.5 M  Tris  
1.5 M  NaCl 
pH 7.6 
7.9.1.1 Detection of HRP-conjugated antibodies 
Nitrocellulose membrane is washed thrice with TBS for 6-10 minutes. Lumigio Reagent 
A (Cell Signaling) and Peroxide Reagent B (Cell Signaling) are mixed at a ratio of 1:1 
and are brought to 1x concentration by dilution with ddH2O. 1,5 ml of solution is used 
to coat one nitrocellulose membrane (5x8cm) and incubated for one minute. Bands are 
detected with CL-XPosure Film (Thermo Scientific) in a dark room using an Agfa 
Curix 60 developer. 
7.9.1.2 Detection of AP-conjugated antibodies 
Membrane is washed three times with TBS-T for 6-10 min each and is then incubated 
with 10 ml AP-Buffer containing 66 µl of NBT (added first) and 33 µl of BCIP (added 
second). Incubation takes place in the dark, within 5-60 minutes bands start appearing. 
Reaction is stopped with ddH2O. 
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AP-Buffer 
100 mM Tris HCl pH9.5 
100 mM  NaCl 
5 mM   MgCl 6 H2O 
 
BCIP 
0.5 g   BCIP 
10 ml   100% Dimethylformamide  
store at 4°C 
NBT 
0.5 g   NBT 
10 ml   70% Dimethylformamide  
store at 4°C 
7.9.2 Stripping of Western Blots 
7.9.2.1 Stripping of primary and secondary antibody 
Membrane is washed thrice for 5 minutes in 1x TBS and is then transferred into a 50 ml 
falcon containing 45 ml Stripping Buffer A. Falcon is placed in a 70°C water bath for 
30 min under constant shaking. Nitrocellulose membrane is repeatedly washed with 1x 
TBS until β-Mercaptoethanol smell has vanished.  
Stripping Buffer A 
2%  SDS 
100 mM  β-Mercaptoethanol 
62.5 mM  Tris-HCl pH 6.8 
7.9.2.2 Stripping of secondary antibody  
Nitrocellulose membrane is incubated in 0.2 M NaOH for 7 minutes at room 
temperature followed by four 6 minute wash steps in TBS-T. Secondary Antibody 
should be removed now. Only use antibodies produced in different donor than the 
previous one.  
7.9.3 Dot Blot 
Dot Blot analysis can be used to estimate protein concentrations of a sample compared 
to known concentrations of the purified protein if a specific antibody is available.  
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2 µl of sample are spotted onto nitrocellulose membrane, each spot should be 
comparable in size and should not exceed 3-4 mm diameter. After membrane has dried 
it is blocked in 5% BSA in TBS-T for one hour at room temperature. Primary antibody 
is diluted in BSA/TBS-T and incubated for at least 30 minutes or longer. Membrane is 
washed thrice with TBS-T for 5 minutes each. Secondary antibody (HRP- or AP- 
conjugated) is diluted in BSA/TBS-T and incubated for at least 30 minutes. For 
detection protocol see 7.9.1.  
TBS 
20 mM  Tris-HCl 
150 mM  NaCl 
pH7.5 
TBS-T  
0.05%  Tween 20 in TBS 
BSA/TBS-T 
0.1%  BSA in TBS-T 
7.10 Isolation of RNA from ESCs and CVPCs 
Cells have to be fed two hours prior to RNA isolation. If cells are grown on feeder cells 
they are trypsinized, resuspended in M15Hy and plated on gelatin-coated wells for 50 
minutes at 37°C, 5% CO2 in order to separate stem cells from feeder cells. Feeder cells 
adhere faster to the gelatin-coated surface of the 6 well plates while ESCs/CVPCs 
remain nonattached for a longer period of time. After 50 minutes of incubation at 37°C, 
5% CO2 supernatant is transferred into a 15 ml falcon. If cells are not grown on feeders 
the preadsorbtion can be left out and cells are trypsinized, resuspended and directly 
transferred to 15 ml falcons. Falcons are rotated for 5 min at 1000 rpm at room 
temperature, and pellet is washed with 4 ml of PBS. Centrifugation step is repeated and 
pellet is resuspended in 1 ml 1x PBS and transferred to an Eppendorf tube. Tubes are 
centrifuged at 14 000 rpm for 5 min at 4°C.  
RNeasy Mini Kit, Qia-shredder protocol 
Pellets are resuspended in 600 µl of RLT buffer-β-Mercaptoethanol (100:1) and loaded 
onto RNeasy Mini Spin Column (pink) and centrifuged at room temperature for 2 
minutes at 13 000 rpm. Column is discarded and 600 µl of 70% EtOH are added to 
flow-through. 600 µl of this suspension are loaded onto QIAshredder Spin Column 
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(purple) and centrifuged for 15 seconds at 13 000 rpm at room temperature. Flow-
through is discarded and the remaining 600 µl of suspension are loaded onto column 
and centrifugation step is repeated. Flow-through is discarded and 700 µl RW1 is 
loaded onto column and centrifugation is repeated as before. After flow through is 
discarded 500 µl of RPE are loaded and centrifuged for 2 minutes at same conditions. 
This last step is repeated once more, the column is transferred into a fresh 2 ml 
collection tube and spun down for 1 minute at 13 000 rpm. Column is transferred into a 
clean Eppendorf tube and 35 µl RNase-Free Water are added and nucleic acids are 
eluted by a 1 minute centrifugation step at 13 000 rpm at room temperature.  
DNA digestion 
3.75 µl DNase 1 buffer and 3.75 µl DNase 1 are added and tube is placed at 37°C for 30 
minutes. To stop the digestion 3.75 µl EDTA are added and tube is placed on shaker for 
10 minutes at 65°C. After this, the tube is stored at -80°C. Successful digestion of DNA 
has to be checked by running a GAPDH PCR. If digestion was successful only positive 
control should show a band at 300bp.  
Reverse Transcription 
RT-Mix 
10 µl  5x Buffer 
5 µl  0.1M DTT 
1.5 µl  RiboLock RNase Inhibtior 
2 µl  10mM dNTPs 
 
1 µl d(T) is added to DNA-free sample and incubated at 70°C for 10 minutes followed 
by 3 minutes on ice and 15 seconds spinning at 13 000 rpm. 18.5 µl RT-Mix are added 
to sample and incubated at 42°C for 2 minutes. 1 µl Revert Aid Reverse Transcriptase is 
added to samples and incubated for 50 minutes at 42°C. This step is followed by 15 
minutes at 70°C and 5 min on ice. After 2 minutes of centrifugation at 13 000 rpm 
samples are stored at -80°C. Concentration of nucleic acids is measured by Nanotrop.  
When comparing samples with each other the amount of sample added to RT-PCR 
master mix must be balanced by GAPDH RT-PCRs first.  
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7.11 PCR 
Mastermix  
38,75 µl  dH2O   
5 µl  10x buffer (Fermentas #EP0402) 
3 µl  25 mM MgCl (Fermentas #EP0402) 
1 µl  10 mM dNTPs (Fermentas #R0192) 
0.5 µl  Forward primer (Vienna BioTec) 
0.5 µl  Reverse primer (Vienna BioTec) 
0.25 µl  Taq Polymerase (Fermentas #EP0402) 
 
A mulitple of the mastermix can be made and aliquots of 49 µl are added to each PCR 
tubes (Klösch) and 0.9-2 µl of sample DNA or cDNA are added. Tubes are placed in 
Biometra T-Personal PCR machine.  
PCR-Program: 
1. 94°C for 60 sec 
2. 94°C for 45 sec 
3. k°C for 45 sec usually 50°C<k<66°C depending on primers 
4. 72°C for 60 sec 
5. Repeat step 2-4 for 28-39 cycles, depending on TM of primers 
6. 72°C for 240 sec 
7. 4°C  
7.12 Immunofluorescence 
Cells are adherent to culture dishes and are washed once with 1x PBS followed by 
addition of 4% Paraformaldehyde. After 20 min at room temperature, cells are washed 
twice with 1x PBS. 0.1% Saponin in 1x PBS is used to permeabilize cells and after 20 
minutes wash step is repeated. Blocking is achieved with 2% BSA in TBS/PBS for 10 
minutes. 1st Antibody is diluted in antibody dilution solution and incubated for 1 h at 
4°C. The application of parafilm on top of cell layer may help to evenly distribute 
antibody. Cells are washed thrice with 1x PBS for ten minutes each followed by an 
incubation with secondary antibody for one hour at 4°C. Cells are washed once with 1x 
PBS for 10 minutes followed by a 10 minute wash step with 1x PBS containing a 
1:1000 dilution of DAPI. After this, cells are washed twice for 10 min with 1x PBS and 
coated with 55°C Mowiol. Coverslip is applied while Mowiol is still warm and slides 
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are stored in the dark. Once Mowiol hardend, cover slips are sealed with non-
fluorescending nail polish. A LSM-Meta 510 (Zeiss) Microscope is used to visualize 
staining.  
Antibody Dilution Solution 
2%  BSA in 1x TBS 
7.13 Karyotyping 
Cells can be treated with 10 µl colchicine (1 µg/ µl) for 3 h prior to trypsinization in 
order to inhibit spindle formation. 
Confluent cells (24 wells) are washed with 1 ml of 1x PBS and 200 µl of trypsin are 
added. After 15-20 min at 37°C 5% CO2 800 µl M15Hy are added and suspension is 
transferred to a 15 ml falcon. This step is followed by 5 min centrifugation at 1000 rpm 
at room temperature. All but 0.5 ml of supernatant are discarded and pellet is 
resuspended in the remaining 0.5 ml. 4 ml of 75 mM KCl buffer (room temperature) are 
added drop-wise. Let stand at room temperature for 6 minutes. After this, suspension is 
centrifuged at room temperature for 5 min at 1000 rpm. Supernatant is removed and 4 
ml of a 3:1 methanol:glacial acetic acid mixture are added with a Pasteur pipette. 
Centrifugation step is repeated, supernatant discarded and 3 ml of methanol:glacial 
acetic acid are added. This step is repeated till a satisfying pellet is achieved. After that 
centrifugation step is repeated once more and 0.5 ml of methanol:glacial acetic acid are 
added. More can be added if dilution of cells is not high enough. Before further use 
suspension should be stored at 4°C for at least 3 h. Wash slides in 70% Ethanol and let 
them dry before use. Place slides at a 30-60° angle and use a Pasteur pipette to create 
individual drops of cells. Drops will run down the slide and thereby spread the cells 
over the entire slide. Place Pasteur pipette between 3-6 cm above slides to achieve better 
results. Suspension can be kept over months at 4°C. 
7.14 Purification of recombinant M-LIF 
The SF9 cell line was derived from pupal ovarian tissue of the fall armyworm 
Spodoptera frugiperda. The SF9 cell line is highly suspectible to infection with 
Autographa California nuclear polyhedrosis virus (AcNPV baculovirus), and can be 
used with all baculovirus expression vectors. SF9 cells are commonly used to isolate 
and propagate recombinant baculoviral stocks and for the productions of recombinant 
proteins. 
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SF9 freezing medium 
20%  Gibco FBS serum 
20%  DMSO 
60%  Sf-900 medium 
 
SF9 culture medium 
93% Sf-900 medium 
1%  Streptomycin 
2%  Gibco serum 
7.14.1 Thawing of SF9 insect cells 
SF9 cells are kept in a liquid nitrogen tank in freezing medium containing 20% Gibco 
FBS Serum. Kryotube is thawed in water bath till only a small icicle remains, sprayed 
with 70% EtOH and flamed before opening. Contents is transferred into 15 ml flasks 
and 12 ml of SF9 20% Gi are added drop by drop. Falcon is centrifuged at room 
temperature for 4 minutes at 1000 rpm. Pellet is resuspended in 1 ml thawing medium 
and another 5 ml of thawing medium are added and mixed well. Suspension is 
transferred into 75cm² culture flask containing 5 ml of thawing medium. Culture at 
28°C but do not close lid fully so that air can circulate. Replace medium after 24h by 
fresh thawing medium to remove dead cells. When cells are confluent scrape them off 
with a Pasteur pipette and transfer them into a falcon and centrifuge for 5 minutes at 
room temperature (RT) at 1000 rpm. Resuspend pellet in Sf-900 15% Gi serum and 
culture till confluent. Reduce serum to 10%, then 5% and finally 2% serum every time 
cells are confluent and split. Sf900 2% Gi is used as regular culture medium.  
Thawing medium 
3,6 ml  Gibco 
16,4 ml  SF9 medium 
7.14.2 Maintenance of SF9 insect cells 
Cells are kept at 28°C in a SF9 culture medium. Lids of culture flasks should not be 
fully closed. Medium should be changed about twice a week.  
7.14.3 Infection of SF9 insect cells 
When density reaches 40x106 cells per culture flask (75cm2) cells are ready to be 
transfected. 40x106 cells are diluted in 20 ml Sf-900 culture medium and baculovirus is 
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added according to the desired MOI. After 96 h cells are scraped off and transferred into 
50 ml falcons. Falcons are centrifuged at 1000 rpm at room temperature for 5 minutes. 
Supernatant is transferred into a new falcon and stored at -80°C. Pellet is washed with 5 
ml of 1x PBS and centrifuged for 5 minutes at room temperature at 1000 rpm. 
Supernatant is discarded and pellet can be stored at -80°C. 
7.14.4 Protein purification from SF9 insect cells 
Cell pellet is thawed on ice and resuspended in 3.5 ml of lysis buffer (use two Eppis). 
After 15 min on ice, use a Douncer to crush cells by moving up and down 
approximately 50 times (on ice). Keep suspension on ice for another 10 minutes and 
centrifuge at 4°C for 20 min at 14 000 rpm. Keep 10 µl of supernatant for analysis. The 
remaining supernatant is divided into four Eppendorf tubes containing approximately 
200 µl of Ni-NTA agarose beads (Quiagen) each. Ni-NTA agarose beads are previously 
pipetted into Eppendorf tubes and spun down for 2 min at 13 000 rpm at RT, 
supernatant is removed and beads should come up to 0.1 ml marker on Eppendorf tube. 
300 µl of lysis buffer are added followed by centrifugation for 2 min at 13 000 rpm at 
RT and removal of supernatant before sample can be added. After addition of 
supernatant to the beads the tubes are rotated on 4°C for at least 2.5 h or overnight. 
After that Eppendorf tubes are centrifuged at 4°C for 5 minutes at 14 000 rpm, 
supernatant is discarded and 500 µl of wash buffer are added and mixed well followed 
by another centrifugation step. Washing is repeated 3 times. 200 µl of elution buffer I 
are added to the beads and tubes are shaken for 10 min at 800 rpm followed by 5 
minutes centrifugation at 4°C at 14 000 rpm. Supernatant is collected and is named 
eluate 1. This step is repeated to achieve eluate 2. 200 µl of elution buffer 2 are used to 
accumulate eluate 3 and another 200 µl of elution buffer 2 to get eluate 4. Eluates are 
stored at 4°C. 
Lysis buffer 
50 mM NaH2PO4 
300 mM NaCl  
10 mM Imidazole 
adjust pH to 8 using 1 M NaOH 
add NP-40 at a dilution of 1:100 directly before use 
add Aprotinin, Leupeptin, Pepstatin A at a dilution of 1:1000 each right before use 
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Wash buffer 
50 mM NaH2PO4 
300 mM NaCl 
10 mM Imidazole 
adjust pH to 8 using 1 M NaOH 
add Aprotinin, Leupeptin, Pepstatin A at a dilution of 1:1000 each right before use 
Elution buffer I 
50 mM NaH2PO4 
300 mM NaCl  
50 mM Imidazole 
adjust pH to 8 using 1 M NaOH 
add Aprotinin, Leupeptin, Pepstatin A at a dilution of 1:1000 each right before use 
Elution buffer II 
50 mM NaH2PO4 
300 mM NaCl 
250 mM Imidazole 
adjust pH to 8 using 1 M NaOH 
add Aprotinin, Leupeptin, Pepstatin A at a dilution of 1:1000 each right before use 
7.14.5 Dialysis of purified protein from SF9 insect cells 
If the purified protein is used for cell culture work it needs to be purified prior to use. 
About 2 cm of cellulose tubular membrane (Roth) per Eppendorf tube is needed. 
Membrane is rinsed with distilled water and then placed in a 50 ml falcon containing 50 
ml of solution 1. Falcon is placed in a 60°C water bath for 3 h in order to remove traces 
of heavy metal ions. Prior to use the membrane is rinsed with distilled water.  
The rear end of a Pasteur pipette is heated over a burner and used to burn holes into the 
lids of sterile Eppendorf tubes. 400 µl of sample are added into each tube and 2 cm of 
membrane tube is cut off and cut open to create a 2 cm x 2 cm surface. Membrane is 
placed on top of Eppendorf tubes and lids are closed, fixating the membrane to the 
tubes. Place tubes upside-down in individual 50 ml falcons and centrifuge for 4 min at 
1000 rpm. Tubes should not leak, in case they do, replace membrane and repeat 
centrifugation step to make sure tubes are sealed well. Tubes are placed upside-down in 
a beaker and placed in 1x PBS at a volume of 1:1000 in relation to the sample amount. 
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The following day content is transferred into fresh Eppendorf tubes and protein 
concentration is measured by Nanodrop.  
Western Blot can be performed to ensure presence of M-LIF protein in solution. 
Previously performed mass spectroscopy (MALDI-TOF) showed that M-LIF makes up 
about 2% of total protein concentration. 
Solution 1 
1 mM EDTA 
2% Sodiumhydrogencarbonate 
7.15 Transfection of CVPCs 
Transfection medium  
83% DMEM 
15% HyClone 
1% L-Glutamine (amino acids) 
1% β-Mercaptoethanol 
24 wells are gelatin-coated two hours prior to use. Confluent cells are trypsinized and 
counted with a CASY counter. 105 cells per well are seeded in 1 ml of transfection 
medium free of antibiotics. Cells are cultured over night and can be transfected the next 
morning.  
7.15.1 Transfection with pGM3-EGFP Vimentin MIDI 
EGFP transfections are used to optimize transfection protocol. DNA to Lipofectamine 
2000 ratio of 1:1 are used. 1 µl of Lipofectamine 2000 is added to 49 µl of DMEM-1% 
Glutamine and kept at room temperature for 5 minutes. 1 µg pGM3-EGFP Vimentin 
MIDI DNA is added to DMEM-1% Glutamine to a total volume of 50 µl and mixture is 
then added to Lipofectamine 2000-DMEM solution. After 20 minutes at room 
temperature the entire 100 µl are added to the cells seeded the day before (after reducing 
the medium to 0.5 ml/well). After three hours of incubation at 37°C, 5% CO2 the 
supernatant is replaced by regular M15Hy culture medium. Efficiency of transfection 
can be visualized in YFP channel on a Zeiss Axio Stereomicroscope after 20h.  
7.15.2 Transfection with plasmid DNA and renilla 
DNA to Lipofectamine 2000 ratio used is 1:1. Renilla to plasmid DNA ratio used is 
1:100. 
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1 µl of Lipofectamine 2000 is added to 49 µl of DMEM-1% Glutamine and kept at 
room temperature for 5 minutes. 1 µg plasmid DNA is added to DMEM-1% Glutamine 
to a total volume of 50 µl and mixture is then added to Lipofectamine 2000-DMEM 
solution. After 20 minutes at room temperature the entire 100 µl are added to the cells 
seeded the day before (after reducing the medium to 0.5 ml per well). After three hours 
of incubation at 37°C, 5% CO2 the supernatant is replaced by regular M15Hy culture 
medium. To see if SPARC, M-LIF, or other proteins have short time influence they can 
be added to cells at this time point. After 48 h wells are washed with 1x PBS twice and 
500 µl of 1x Passive lysis buffer are added. With the help of a pipette tip contact 
surfaces for the lysis buffer are scraped. After 50 min cells are resuspended and 
transferred into an Eppendorf tube. Wells are washed with 100 µl of 1x Lysisbuffer. 6 
µl of sample are diluted with 30 µl of 1x lysis buffer and 20 µl of the mixture are 
transferred onto 96 well micro plate. Make sure samples are mixed well before any 
dilution step. Renilla and firefly values are measured with a LB960 Microplate 
Luminometer (Berthold Technologies). Renilla values are measured as an internal 
control to determine transfection efficiency per well. Therefore, firefly values are 
divided by the renilla values in order to create comparable results.  
Passive lysis buffer 
Promega Dual-Luciferase Reporter Assay System Kit #E19910 
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8 Appendix 
8.1 Differentiation 
control beating CBs Total CBs percentage intensity 
d9 0 38 0 0 
d10 0 38 0 0 
d11 2 38 5 2 
d12 13 54 24 5 
d13 36 63 57 10 
d14 58 63 92 15 
d15 58 62 94 16,5 
d16 58 62 94 18 
d17 63 63 100 24 
d18 63 63 100 21,5 
d19 61 63 97 16 
d20 63 63 100 20,5 
d21 63 63 100 18,5 
Table 11 Cardiomyogenesis in CBs (Figure 34). A5p47 (4.4x104 cells/ml). Data is total of 6 control wells. Number 
of beating CBs was determined daily. Intensity of beating was quantified on a scale from 0 (no activity) to 6 (>70% 
of the area contracting) and represents sum of all 6 control wells. 
treatment period (d) 0-4.7 4.7-7 7-10 10-13 
M-LIF 0,13 0,98 0,52 0,40 
BMP2 1,17 1,49 1,50 1,38 
M-LIF+BMP2 0,17 1,05 0,70 0,47 
anti-LIF 1,37 1,17 0,87 1,47 
anti-BMP2/4 1,03 1,01 0,92 0,85 
control 1,00 1,00 1,00 1,00 
Table 12 Beating intensity of CBs (Figure 38). CBs were treated with M-LIF (100ng/ml), BMP2 (100ng/ml), anti-
BMP2/4 antibodies (500 µg/ml), anit-LIF antibodies (1 µg/ml), and BMP2 and M-LIF combined, respectively. 
Substances were added on day 1 of treatment period. Treatment periods were day 0-4.7, day 4.7-7, day 7-10, and day 
10-13, respectively. 6 control plates were left untreated. Areas of beating cardiomyocytes per CB were quantified 
daily on a scale from 0 (no activity) to 6 (>70% of the area contracting). Values of day 0-20 were added and set 
relative to control. Control values can be seen in Table 11. 
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8.2 Transfections 
 
NKE 
 
Firefly (FF) 
 
Renilla (R) 
A 
FF/R 
 
Mean 
 
σ 
blank value 180 650 0.2769   
control 4240 147750 0.0287 0.0299 0.0023 
 4070 124990 0.0326   
 4440 156220 0.0284   
BMP2 3480 163870 0.0212 0.0254 0.0045 
 4630 153730 0.0301   
 4410 178290 0.0247   
SPARC 4810 191430 0.0251 0.0244 0.0006 
 3780 158340 0.0239   
 3640 149770 0.0243   
      
blank value 180 650 0.2769   
control 2330 35490 0.0657 0.0631 0.0048 
 2560 38720 0.0661   
 1680 29180 0.0576   
BMP2 3730 52030 0.0717 0.0692 0.0101 
 3070 39460 0.0778   
 2810 48350 0.0581   
SPARC 2340 44790 0.0522 0.0579 0.0058 
 2760 48070 0.0574   
 3210 50230 0.0639   
Table 13 Nkx2.5 activation by BMP2 and SPARC (Figure 46). A5p27 (A) and A5p14 (B) were transfected with 
the NKE24 plasmid and the Renilla plasmid at a ratio of 100:1. BMP2 and SPARC have no influence on Nkx2.5 
promoter activation 48h post transfection. 
transfected 
plasmids 
FF R FF/R FF/R/ 
[pGL3b] 
Mean 
value 
Standard 
deviation 
NKE+pUC 5000 46110 0.1084 60.93 48.38 17.75 
 4610 72310 0.0638 35.82   
NKE+Desmin+pUC 4070 96980 0.0420 23.58 21.56 2.86 
 4600 132300 0.0348 19.54   
NKE+Desmin+kd 4 1790 54010 0.0331 18.62 17.29 1.89 
 1950 68690 0.0284 15.95   
NKE+Desmin+kd-
ct 
6690 180880 0.0370 20.78 21.80 1.44 
 6710 165230 0.0406 22.82   
NKE+kd-4+pUC 2800 89110 0.0314 17.66 17.31 0.49 
 2410 79810 0.0302 16.97   
pGL3b+pUC 540 309390 0.0017 1.00   
 490 270150 0.0018    
blank 280 500 0.5600    
Table 14 Luciferase Assay of CVPC clone A5 (Figure 47A). 330 ng of each plasmid was used (Renilla 10 ng), 
vector pUC was used to compensate to a total of 1000 ng. Firefly values (FF), Renilla values (R), Firefly relative to 
Renilla (FF/R), FF/R relative to pGL3b (FF/R[pGL3b]). 
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transfected 
plasmids 
FF R FF/R FF/R/ 
[pGL3b 
F/R] 
Mean 
value 
Standard 
deviation 
NKE+pUC 1390 8580 0.16 15.09 12.13 4.19 
  1420 14440 0.10 9.16     
NKE+Desmin+pUC 1350 20500 0.07 6.13 5.68 0.65 
  1120 19980 0.06 5.22     
NKE+Desmin+kd 4 1060 14600 0.07 6.76 12.12 7.58 
  730 3890 0.19 17.48     
NKE+Desmin+kd-
ct 1740 20790 0.08 7.80 6.01 2.53 
  1920 42430 0.05 4.22     
NKE+kd-4+pUC 940 19300 0.05 4.54 5.23 0.99 
  1970 30940 0.06 5.93     
NKE+kd-ct+pUC 3140 59830 0.05 4.89 4.98 0.13 
  3570 65510 0.05 5.08     
pGL3b+pUC 380 35400 0.01 1.00   
blank 280 620 0.45    
Table 15 Luciferase Assay of CVPC clone A5 (Figure 47B). 330 ng of each plasmid was used (Renilla 10 ng), 
vector pUC was used to compensate to a total of 1000 ng. Firefly values (FF), Renilla values (R), Firefly relative to 
Renilla (FF/R), FF/R relative to pGL3b (FF/R[pGL3b]). The values that are highlighted red were not incorporated in 
graphic. 
transfected 
plasmids 
FF R FF/R FF/R/ 
[pGL3b 
F/R] 
Mean 
value 
Standard 
deviation 
NKE+pUC 3170 33090 0.0958 30.32 31.26 1.33 
  4090 40200 0.1017 32.20     
NKE+Desmin+pUC 2630 37050 0.0710 22.47 18.10 2.96 
  2590 48440 0.0535 16.92     
 1830 36430 0.0502 15.90   
 2830 52360 0.0540 17.11     
NKE+Desmin+kd 4 970 15120 0.0642 20.30 18.44 1.38 
 1190 20280 0.0587 18.57     
 1240 22040 0.0563 17.81   
  1380 25570 0.0540 17.08   
NKE+Desmin+kd-
ct 1470 19320 0.0761 24.08 25.72 2.40 
  1640 22300 0.0735 23.28     
 1420 15990 0.0888 28.11   
 1480 17080 0.0867 27.42     
NKE+kd-4+pUC 1410 27890 0.0506 16.00 16.49 0.69 
  1850 34480 0.0537 16.98     
NKE+kd-ct+pUC 4200 75870 0.0554 17.52 16.88 0.90 
  3580 69760 0.0513 16.24     
pGL3b+pUC 330 110520 0.0030   1.00   
 310 93000 0.0033       
blank 270 571 0.4729    
 250 550 0.4545    
Table 16 Luciferase Assay of CVPC clone A5 (Figure 47C) 330 ng of each plasmid was used (Renilla 10 ng), 
vector pUC was used to compensate to a total of 1000 ng. Firefly values (FF), Renilla values (R), Firefly relative to 
Renilla (FF/R), FF/R relative to pGL3b (FF/R[pGL3b]). 
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10 Zusammenfassung 
Herz-Kreislauf-Erkrankungen sind weltweit die häufigste Todesursache. Allein in 
Österreich stirbt fast jede zweite Person an Herz-Kreislauf-Erkrankungen. Das adulte 
Herz wurde lange Zeit für ein post-mitotisches Organ ohne regenerativer Kapazität 
gehalten. Dadurch wäre ein Herzinfarkt verursachtes Sterben von Kardiomyozyten 
irreversibel. Innerhalb der letzten Jahre wurde das Vorhandensein von 
Herzvorläuferzellen von verschiedenen Arbeitsgruppen gezeigt. Eine in-vivo 
Aktivierung und Differenzierung dieser Zellen würde neue Therapiemöglichkeiten für 
Herzinfarkt-Patienten eröffnen. Daher ist die Untersuchung der 
Signaltransduktionskaskaden die der Aktivierung und Differenzierung dieser 
Vorläuferzellen unterliegen essentiell und würde zu einem besseren Verständnis der 
Selbsterneuerungskapazität des murinen Herzens beitragen.  
In dieser Arbeit berichten wir über die Isolierung einer stabilen, euploiden, murinen 
Herz-Vorläufer-Zelllinie (cardiovascular progenitor cell (CVPC) line). Wir konnten 
diese Zellen über 60 Passagen kultivieren ohne einen Verlust der 
Selbsterneuerungskapazität oder einer Minderung der Potenz festzustellen. CVPCs 
exprimieren die Stammzellmarker Oct3/4, Nanog und Sox2 gleichzeitig mit den 
Herzzellmarker Nkx2.5, Mef2c und GATA4. Letzeres steht im Gegensatz zu murinen 
embryonalen Stammzellen (mESCs). Die Expression dieser Herzzellmarker steht im 
Einklang mit der Potenz-Limitierung dieser Zellen im Vergleich zu mESCs. CVPCs 
differenzieren ausschließlich zu Zellen des Herzens, nämlich Kardiomyozyten, glatter 
Muskelzellen und Endothelzellen. Sowohl die Expression von Herzellmarkern im 
undifferenzierten Zustand als auch die Limitierung des Differenzierungspotentials sind 
Hinweise darauf, dass CVPCs bereits auf die Differenzierung zu Zellen des Herzens 
eingeschränkt sind. Die Differenzierung von CVPCs wird durch den Entzug von 
Leukemia Inhibitory Factor (LIF) eingeleitet und ist unabhängig von anderen 
induzierenden Faktoren. LIF ist nötig und hinreichend um die Selbsterneuerung von 
CVPCs zu erhalten und hat einen negativen Effekt auf die Differenzierung von CVPCs. 
Eine zeitlich begrenzte Inhibierung der LIF-Signalgebung unterstützt die 
Differenzierung von CVPCs und Bone Morphogentic Protein 2 erhöht die 
Differenzierung zu Kardiomyocyten im Cardiac Body System signifikant.  
CVPCS unterscheiden sich deutlich von den häufig untersuchten mESCs. Da ihr 
Potential limitiert ist und CVPCs bereits auf die Differenzierung zu Zellen des Herzens 
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eingeschränkt sind, stellen sie verglichen mit mESCs ein niedrigeres Risiko in 
Stammzelltransplantationen dar. Weitere Untersuchungen von CVPCs werden zu einem 
besseren Verständnis der Selbsterneuerungskapazität des murinen Herzens führen. 
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11 Abstract 
Cardiovascular Diseases are the leading cause of death globally and account for almost 
one out of two deaths in Austria. The adult heart was thought to be a post-mitotic organ 
without a regenerative capacity. Therefore cell death of cardiomyocytes after 
myocardial infarction (MI) was believed to be irreversible. Recently, the existence of 
cardiovascular progenitor cells in the adult heart was demonstrated by various groups. 
The activation and differentiation of these cells in vivo would provide a new therapy 
option for MI patients. Therefore, the study of the cell signaling cascades underlying 
cardiomyocyte differentiation and cardiovascular progenitor cell activation in vitro 
would benefit the better understanding of the in vivo regenerative capacity of the 
murine heart. 
Here we report the isolation of a stable, euploid murine cardiovascular progenitor cell 
(CVPC) line. We successfully cultured these cells for over 60 passages without a loss of 
self-renewal capacity or a decrease in potency. CVPCs express stemness factors Oct3/4, 
Nanog, and Sox2 simultaneously with cardiac markers Nkx2.5, Mef2c, and GATA4, the 
latter stands in contrast to murine embryonic stem cells (mESCs). The expression of 
cardiac markers in the undifferentiated state of CVPCs goes hand in hand with the 
potency-limitations of these cells compared to mESCs. CVPCs are restricted to 
differentiate to cell types of the cardiac lineage, namely cardiomyocytes, smooth muscle 
cells, and endothelium. The expression of cardiac markers in the undifferentiated state 
and the limitation of the differentiation potential indicate that CVPCs are already 
committed to give rise to cells of the cardiac lineage. The differentiation of CVPCs is 
induced upon Leukemia Inhibitory Factor (LIF) deprivation and is not dependent on 
other inductive signals. Furthermore, LIF is necessary and sufficient to maintain self-
renewal of CVPCs and has a negative effect on differentiation. Inhibition of LIF 
signaling aids differentiation of CVPCs and Bone Morphogenetic Protein 2 significantly 
enhances differentiation to cardiomyocytes in the Cardiac Body system in a time 
dependent manner.  
CVPCs are clearly distinct from the most commonly studied mESCs. Since their 
potential is limited and CVPCs are committed to the cardiac lineage, they bear lower 
risks than mESCs in stem cell transplantation approaches. Further investigation of 
CVPCs will contribute to a better understanding of the self-renewal capacity of the 
murine heart. 
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